Substituted tolyl as fungicides
Tolyl fungicides and their derivatives offer a solution to control plant diseases by providing efficient, less toxic, and environmentally safer alternatives with a unique mode of action against fungal pathogens.
Patent Information
- Application Number
- JP2024141783
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-11-06
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-11-05
AI Technical Summary
There is a need for new fungicides that are more efficient, less toxic, less expensive, and safer for the environment, with a different site of action to control plant diseases caused by fungal pathogens.
Development of tolyl fungicides, their N-oxides, and salts, including compounds of Formula 1, which are used in agricultural compositions to combat fungal plant pathogens, and can be combined with other fungicides or agents to enhance efficacy.
The compounds provide effective control of plant diseases by interfering with the fungal life cycle, offering a different mode of action that reduces resistance and environmental impact.
Smart Images

Figure 2024167276000001 
Figure 2024167276000002 
Figure 2024167276000003
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to certain tolyl fungicides, their N-oxides, salts, and compositions, and methods of their use as fungicides. [Background technology]
[0002] 2. Background of the Invention Control of plant diseases caused by fungal plant pathogens is very important in achieving high yield efficiency. Plant diseases that damage ornamental plants, vegetables, field crops, cereals, and fruit crops can cause significant reductions in productivity and thus increase costs for consumers. Although many products are commercially available for these purposes, there is a continuing need for new compounds that are more efficient, less expensive, less toxic, safer for the environment, or have different sites of action.
[0003] US Patent Nos. 5,233,333, 5,293,422, 5,396,603, and 5,441,633 disclose toryl fungicides and their use in agriculture. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] PCT International Publication WO2015157005 [Patent Document 2] PCT International Publication WO2014066120 [Patent Document 3] PCT International Publication WO2011059619 [Patent Document 4] PCT International Publication WO2008124092 Summary of the Invention [Means for solving the problem]
[0005] Summary of the Invention The present invention relates to a compound of formula 1: [ka] [In the formula, A is, [ka] is a radical selected from the group consisting of where the bond extending to the right is attached to the ring containing Q and the bond extending to the left is YN(R 3 )C(=W)R 4 attached to a substituted phenyl ring; Q is CR 6 or N; Y is CR 7a R 7b , O or NR 8 and; W is O or S; R 1 and R 2 each independently represents halogen, cyano, hydroxy, nitro, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 cyanoalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C4-C8 cycloalkylalkyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl aloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 cyanoalkoxy, C3-C6 cycloalkoxy, C4-C8 cycloalkylalkoxy, C2-C6 alkoxyalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl or C1-C6 haloalkylsulfonyl; R 3is H, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl or C2-C4 haloalkoxycarbonyl; R 4 is C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylamino or C2-C4 dialkylamino; Each R 5 are independently halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, or C1-C3 haloalkoxy; n is 0, 1 or 2; R 6 is H, halogen, cyano, hydroxy, nitro, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 cyanoalkyl, C1-C6 hydroxyalkyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyloxy, C2-C6 halo Alkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 cyanoalkoxy, C2-C6 alkoxyalkoxy, C1-C6 alkylamino, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, -ZC(=O)V, CR 10a =NOR 10b , ON=CR 11a R 11b , C.R. 12a =NNR 12b R 12c or -LJ; R 7a is H, hydroxy, halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylsulfinyl or C1-C3 alkylsulfonyl; R7b is H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkoxyalkyl, C1-C3 alkoxy or C1-C3 haloalkoxy; R 8 is H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkylcarbonyl or C2-C3 haloalkylcarbonyl; Z is a direct bond, O, S, or NH; or CH2 optionally substituted with up to two substituents independently selected from halogen, methyl, or methoxy; V is R 9 OR 9 and; R 9 , R 10b , R 11a and R 12c are each H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, or C4-C8 cycloalkylalkyl; R 10a , R 11b , R 12a and R 12b are each independently H, C1-C3 ar alkyl or C1-C3 haloalkyl; L is a direct bond, CH2, O, S, NR 13 , OCH2, CH2O, C(=O), S(=O) or S(=O)2; J is a 3-6 membered non-aromatic carbocyclic ring, where up to 3 carbon atom ring members are independently selected from C(=O) and C(=S), and each ring is selected from R 14 optionally substituted with up to four substituents independently selected from J is a 3-6 membered heterocyclic ring, each ring containing ring members selected from carbon atoms and 1-4 heteroatoms independently selected from up to 2 O atoms, up to 2 S atoms, and up to 4 N atoms, where up to 3 carbon atom ring members are independently selected from C(=O) and C(=S), and each ring is selected from R 14optionally substituted with up to four substituents independently selected from: R 13 is H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkylcarbonyl or C2-C3 haloalkylcarbonyl; Each R 14 are independently halogen, hydroxy, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C1-C4 alkoxy, C1-C4 haloalkoxy, or C(=O)OR 15 and Each R 15 are independently H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, or C3-C6 halocycloalkyl. (including all stereoisomers), their N-oxides and salts, agricultural compositions containing them and their use as fungicides.
[0006] More particularly, the present invention relates to compounds of formula 1 (including all stereoisomers), N-oxides or salts thereof:
[0007] The present invention also relates to a germicidal composition comprising: (a) a compound of the present invention (i.e., in a germicidal effective amount); and (b) at least one additional component selected from the group consisting of a surfactant, a solid diluent, and a liquid diluent.
[0008] The present invention also relates to fungicidal compositions comprising: (a) a compound of the present invention; and (b) at least one other fungicide (eg, at least one other fungicide having a different site of action).
[0009] The present invention further relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to a plant or part thereof, or to the seeds of a plant, a fungicidally effective amount of a compound of the invention (e.g., as a composition described herein).
[0010] The present invention also relates to compositions comprising Formula 1, an N-oxide, or a salt thereof, and at least one invertebrate pest control compound or agent. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT As used herein, the terms "comprises," "comprising," "includes," "including," "having," "having," "containing," "featured by," or any variations thereof, are intended to cover inclusive inclusion subject to any limitations expressly stated. For example, a composition, mixture, process, method, article, or device that includes a list of elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or device.
[0012] The transitional phrase "consisting of" excludes any element, step, or ingredient not specified. In the case of a claim, such phrase will close the claim against the inclusion of materials other than those recited, except for impurities ordinarily associated therewith. When the phrase "consisting of" appears in a passage in the body of a claim rather than immediately following the preamble, it limits only the elements recited in that passage; other elements are not excluded from the claim as a whole.
[0013] The transitional phrase "consisting essentially of" is used to define a composition, method, or apparatus that includes materials, steps, features, ingredients, or elements in addition to those literally disclosed, provided that these additional materials, steps, features, ingredients, or elements do not materially affect the basic and novel characteristics of the claimed invention. The term "consisting essentially of" is intermediate between "comprising" and "consisting of."
[0014] Where applicants have defined the invention or portions thereof using open-ended terms such as "comprising," it is to be understood that (unless otherwise indicated) the description shall also be construed to describe the invention using the terms "consisting essentially of" or "consisting of." Further, unless expressly stated to the contrary, "or" refers to an inclusive or and not an exclusive or. For example, a condition A or B can be satisfied by any one of the following: A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist).
[0015] Also, the indefinite articles "a" and "an" preceding an element or component of the invention are intended to be open ended regarding the number of instances (i.e., occurrences) of that element or component. Thus, "a" or "an" shall be read to include one or at least one, and the singular form of the element or component also includes the plural, unless the number is clearly meant to be singular.
[0016] As referred to in this disclosure and claims, "plants" include members of the Plantae kingdom, particularly Spermatopsida, in all life stages, including young plants (e.g., emerging seeds that develop into seedlings) and mature reproductive stages (e.g., plants that produce flowers and seeds). Plant parts also include geotropic members that typically grow below the surface of a growing medium (e.g., soil), such as roots, tubers, bulbs, and corms, as well as members that grow above a growing medium, such as foliage (including stems and leaves), flowers, fruits, and seeds.
[0017] As referred to herein, the term "seedling", either alone or in combination, means the young plant that develops from the embryo of a seed.
[0018] As referred to herein, the term "broadleaf," used either alone or in terms such as "broadleaf crops," refers to dicotyledons or dicotyledons, a term used to describe a group of angiosperms characterized by an embryo with two cotyledons.
[0019] As referred to in this disclosure, the terms "fungal pathogens" and "fungal plant pathogens" include pathogens in the phyla Ascomycota, Basidiomycota and Zygomycota, as well as fungal-like Oomycota, that are the causative agents of a wide range of economically important plant diseases affecting ornamental plants, turfgrass, vegetable, sports fields, cereal and fruit crops. In the context of this disclosure, "preventing plants from disease" or "controlling plant diseases" includes preventative effects (interrupting the fungal cycle of infection, establishment, symptom development and spore production) and / or therapeutic effects (inhibiting the establishment of plant host tissue).
[0020] As used herein, the term "Mechanism of Action" (MOA) refers to a fungicide that is a compound of the Fungicide Resistance Action Committee (Fungicide Resistance Action Committee). The FRAC-defined mechanisms of action are as defined by the FRAC (FRAC Classification of Biochemical Actions) and are used to distinguish fungicides according to their biochemical mechanism of action in the biosynthetic pathway of plant pathogens, as well as their resistance risk. The FRAC-defined mechanisms of action include: (A) nucleic acid synthesis, (B) mitosis and cell division, (C) respiration, (D) amino acid and protein synthesis, (E) signal transduction, (F) lipid synthesis and cell membrane integrity, (G) cell membrane sterol biosynthesis, (H) cell wall biosynthesis, (I) cell wall melanin synthesis, (P) host plant defense induction, (U) unknown mechanism of action, (NC) unclassified, (M) multisite contact activity, and (BM) biologics with multiple mechanisms of action. Each mechanism of action (i.e., letters A-BM) contains one or more subgroups (e.g., A contains subgroups A1, A2, A3, and A4) based on either the individual effective target site of action or, if the exact target site is unknown, based on cross-resistance profiles within the group or in relation to other groups. Each of these subgroups (e.g., A1, A2, A3, and A4) is assigned a FRAC code (number and / or letter). For example, the FRAC code for subgroup A1 is 4. Further information regarding target sites and FRAC codes can be obtained from publicly available databases, for example maintained by FRAC.
[0021] As used herein, the term "cross-resistance" refers to the phenomenon that occurs when a pathogen develops resistance to one fungicide and simultaneously becomes resistant to one or more other fungicides that are typically, but not always, in the same chemical class or have the same target site of action, or can be detoxified by the same mechanism.
[0022] Generally, when molecular fragments (i.e., radicals) are represented by a series of atomic symbols (e.g., C, H, N, O, and S), the potential or attachment points are readily recognized by one of ordinary skill in the art. In some instances herein, the point of attachment may be explicitly indicated by a hyphen ("-"), particularly when alternative points of attachment are possible. For example, "-NCS" indicates that the point of attachment is the nitrogen atom (i.e., isothiocyanato rather than thiocyanato).
[0023] As used herein, the term "alkylating agent" refers to a chemical compound in which a carbon-containing radical is bonded through a carbon atom to a leaving group, such as a halide or sulfonate, which is displaceable by the attachment of a nucleophile to said carbon atom. Unless otherwise indicated, the term "alkylation" does not limit the carbon-containing radical to an alkyl; the carbon-containing radical in an alkylating agent can be, for example, R 1 and R 2 These include the various carbon-bonded substituent radicals specified for
[0024] In the above description, the term "alkyl", used either alone or in compound words such as "alkylthio" or "haloalkyl", includes straight-chain or branched alkyl, such as methyl, ethyl, n-propyl and i-propyl, or the various butyl, pentyl or hexyl isomers. "Alkenyl" includes straight-chain or branched alkenes, such as ethenyl, 1-propenyl, 2-propenyl, and the various butenyl, pentenyl and hexenyl isomers. "Alkenyl" also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. "Alkynyl" includes straight-chain or branched alkynes, such as ethynyl, 1-propynyl, 2-propynyl, and the various butynyl, pentynyl and hexynyl isomers. "Alkynyl" can also include moieties consisting of multiple triple bonds, such as 2,5-hexadiynyl.
[0025] "Alkoxy" includes, for example, methoxy, ethoxy, n-propyloxy, i-propyloxy, and the different butoxy, pentoxy and hexyloxy isomers. "Alkoxyalkyl" denotes alkoxy substitution on alkyl. Examples of "alkoxyalkyl" include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2C Examples of "alkenyloxy" include straight or branched alkenyls bonded to and linked through an oxygen atom. Examples of "alkenyloxy" include H2C=CHCHO, (CH3)2C=CHCHO, CH3CH=CHCHO, CH3CH=C(CH3)CHO, and CH2=CHCH2CH2O. "Alkynyloxy" includes straight or branched alkynyls bonded to and linked through an oxygen atom. Examples of "alkynyloxy" include HC≡CCHO, CH3C≡CCHO, and CH3C≡CCH2CH2O. "Alkoxyalkoxy" refers to an alkoxy substituent on another alkoxy moiety. Examples of "alkoxyalkoxy" include CH3OCHO, CH3OCHO, and CH3CHOCH2O.
[0026] "Alkylthio" includes branched or straight chain alkylthio moieties, such as methylthio, ethylthio, and the various propyl, butyl, pentyl, and hexylthio isomers. "Alkylsulfinyl" includes both enantiomers of alkylsulfinyl groups. Examples of "alkylsulfinyl" include CH3S(=O), CH3CH2S(=O), CH3CH2CH2S(=O), (CH3)2CHS(=O) and the various butylsulfinyl, pentylsulfinyl, and hexylsulfinyl isomers. Examples of "alkylsulfonyl" include CH3S(=O), CH3CH2S(=O), CH3CH2CH2S(=O), (CH3)2CHS(=O) and the various butylsulfonyl, pentylsulfonyl, and hexylsulfonyl isomers.
[0027] "Alkylamino" includes NH radicals substituted with straight or branched alkyl. Examples of "alkylamino" include CHNH, CHCHNH, CHCHCHNH, and (CH)CHNH. Examples of "dialkylamino" include (CH)N, (CHCH)N, and CHCH(CH)N.
[0028] The term "cycloalkyl" refers to a saturated carbocyclic ring of between 3 and 6 carbon atoms linked together by single bonds. Examples of "cycloalkyl" include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term "cycloalkylalkyl" refers to cycloalkyl substitution on an alkyl group. Examples of "cycloalkylalkyl" include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyls bonded to straight-chain or branched alkyl groups. The term "cycloalkoxy" refers to cycloalkyls bonded to and linked through an oxygen atom, such as cyclopentyloxy and cyclohexyloxy. "Cycloalkylalkoxy" refers to cycloalkyl substitution on an alkoxy group. Examples of "cycloalkylalkoxy" include cyclopropylmethoxy, cyclopentylethoxy, and other cycloalkyl moieties bonded to straight-chain or branched alkoxy groups.
[0029] "Alkylcarbonyl" refers to a straight or branched alkyl group attached to a C(=O) moiety. Examples of "alkylcarbonyl" include CH3C(=O), CH3CH2CH2C(=O), and (CH3)2CHC(=O). Examples of "alkoxycarbonyl" include CH3OC(=O), CH3CH2OC(=O), CH3CH2CH2OC(=O), and (CH3)2CHOC(=O).
[0030] The term "halogen", either alone or in compound words such as "haloalkyl", or in descriptions such as "alkyl substituted with halogen", includes fluorine, chlorine, bromine, or iodine. Furthermore, when used in compound words such as "haloalkyl" or in descriptions such as "alkyl substituted with halogen", said alkyl may be partially or fully substituted with halogen atoms, which may be the same or different. Examples of "haloalkoxy" include F3C, ClCH2, CF3CH2, and CF3CCl2. Terms such as "haloalkoxy" are defined analogously to "haloalkyl". Examples of "haloalkoxy" include CF3O, CCl3CH2O, F2CHCH2CH2O, and CF3CH2O.
[0031] "Cyanoalkyl" refers to an alkyl group substituted with one cyano group. Examples of "cyanoalkyl" include NCCH2, NCCH2CH2, and CH3CH(CN)CH2. The term "cyanoalkoxy" refers to an alkyloxy group substituted with one cyano group. Examples of "cyanoalkoxy" include NCCH2O, NCCH2CH2O, and CH3CH(CN)CHO. "Hydroxyalkyl" refers to an alkyl group substituted with one hydroxy group. Examples of "hydroxyalkyl" include HOCH2CH2, CH3CH2(OH)CH, and HOCH2CH2CH2CH2.
[0032] The total number of carbon atoms in the substituent is "C i -C j" prefix, where i and j are numbers from 1 to 6. For example, C1-C3 alkylsulfonyl designates methylsulfonyl to propylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of 4 carbon atoms, examples of which include CH3CH2CH2OCH2 and CH3CH2OCH2CH2.
[0033] The term "unsubstituted" in reference to a group such as a ring means that the group does not have any substituents other than its one or more bonds to the remainder of Formula 1. The term "optionally substituted" means that the number of substituents may be zero. Unless otherwise indicated, an optionally substituted group may be substituted with as many optional substituents as can be accommodated by replacing hydrogen atoms with non-hydrogen substituents on any available carbon or nitrogen atom. Generally, the number of optional substituents (if any) ranges from 1 to 3. As used herein, the term "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted" or the term "(un)substituted".
[0034] The number of optional substituents may be limited by the limitations stated. For example, the phrase "R 14 "Optionally substituted with up to four substituents independently selected from" means that there may be 0, 1, 2, 3 or 4 substituents present.
[0035] When a compound is substituted with a substituent having a subscript indicating that the number of the substituents may vary (e.g., (R 5 ) n ), the substituents are independently selected from the group of substituents defined, unless otherwise indicated. When a variable is indicated as being optionally substituted at a position, for example, n may be 0 (R 5 ) n, hydrogen may be present at any position not recited in the definition of a variable.
[0036] The naming of substituents in this disclosure uses recognized terms that provide simplicity in precisely conveying the chemical structure to one of ordinary skill in the art. For the sake of brevity, locant descriptors may be omitted.
[0037] Unless otherwise indicated, a "ring" (e.g., J) as a component of Formula 1 is carbocyclic or heterocyclic. The term "ring member" refers to an atom (e.g., C, O, N, or S) or other moiety (e.g., C(=O) and C(=S)) that forms the backbone of a ring or ring. The term "aromatic" indicates that the ring atoms each lie essentially in the same plane, and the p orbitals are perpendicular to the ring plane, and (4n+2) pi electrons, where n is a positive integer, are associated with the ring in a manner that satisfies Hückel's rule.
[0038] The term "carbocyclic ring" refers to a ring in which the atoms forming the ring backbone are selected only from carbon. Unless otherwise specified, a carbocyclic ring may be a saturated, partially unsaturated, or fully unsaturated ring. If a fully unsaturated carbocyclic ring satisfies Hückel's rule, the ring is also called an "aromatic ring." "Saturated carbocyclic" refers to a ring having a backbone made of carbon atoms connected to each other by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.
[0039] As used herein, the term "partially unsaturated ring" or "partially unsaturated heterocycle" refers to a ring that contains unsaturated ring atoms and one or more double bonds, but is not aromatic.
[0040] The term "heterocyclic ring" or "heterocycle" refers to a ring in which at least one of the atoms forming the ring backbone is other than carbon. Unless otherwise indicated, a heterocyclic ring may be saturated, partially unsaturated, or fully unsaturated. If a fully unsaturated heterocyclic ring satisfies Hückel's rule, the ring is also called a "heteroaromatic ring" or an aromatic heterocyclic ring. A "saturated heterocyclic ring" refers to a heterocyclic ring that contains only single bonds between ring members.
[0041] Unless otherwise indicated, the heterocyclic ring is attached to the remainder of Formula 1 through any available carbon or nitrogen atom by replacing a hydrogen on that carbon or nitrogen atom.
[0042] The compounds of the present invention may exist as one or more stereoisomers. Stereoisomers are isomers that have the same constitution but differ in the spatial arrangement of their atoms, and include enantiomers, diastereomers, cis- and trans-isomers (also known as geometric isomers) and atropisomers. Atropisomers arise as a result of restricted rotation around a single bond when the rotation barrier is high enough to allow the isolation of the isomeric species. As will be appreciated by those skilled in the art, one stereoisomer may be more active and / or exhibit beneficial effects when enriched relative to other stereoisomers or separated from other stereoisomers. Furthermore, those skilled in the art know how to separate, enrich and / or selectively prepare the above stereoisomers. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, Stereochemistry of Organic Compounds, John Wiley & Sons, 1994.
[0043] The compounds of the present invention may exist as one or more conformers due to restricted rotation about the amide bond (e.g., C(=O)-N) in Formula 1. The present invention includes mixtures of conformers. Additionally, the present invention includes compounds that are enriched in one conformer relative to another.
[0044] The present invention includes all stereoisomers, conformations and mixtures thereof in all ratios as well as isotopic forms such as deuterated compounds.
[0045] Those skilled in the art will appreciate that not all nitrogen-containing heterocycles are capable of forming N-oxides, since the nitrogen requires an available unshared electron pair for oxidation to the oxide; those skilled in the art will recognize those nitrogen-containing heterocycles that are capable of forming N-oxides. Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are well known to those skilled in the art, and include the synthesis of heterocycles and tertiary amines using peroxyacids such as peracetic acid and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as t-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, for example in: T. L. Gilchrist, Comprehensive Organic Synthesis, Vol. 7, pp. 748-750, ed. S. V. Ley, Pergamon Press; M. Tisler and See B. Stanovnik, Comprehensive Heterocyclic Chemistry, Vol. 3, pp. 18-20, edited by A. J Boulton and A. McKillop, Pergamon Press; M. R. Grimmett and B. R. T. Keene, Advances in Heterocyclic Chemistry, Vol. 43, pp. 149-161, edited by A. R. Katritzky, Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry, Vol. 9, pp. 285-291, edited by A. R. Katritzky and A. J Boulton, Academic Press; and G. W. Cheeseman and E. S. G. Werstiuk in Advances in Heterocyclic Chemistry, Vol. 22, pp. 390-392, edited by A. R. Katritzky and A. J Boulton, Academic Press.
[0046] Those skilled in the art will recognize that salts of chemical compounds are in equilibrium with their corresponding non-salt forms in the environment and under physiological conditions, and therefore the salts share the biological utility of the non-salt forms. Thus, a wide variety of salts of compounds of formula 1 are useful (i.e., agronomically suitable) for controlling plant diseases caused by fungal plant pathogens. Salts of compounds of formula 1 include acid addition salts with inorganic or organic acids such as hydrobromic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, acetic acid, butyric acid, fumaric acid, lactic acid, maleic acid, malonic acid, oxalic acid, propionic acid, salicylic acid, tartaric acid, 4-toluenesulfonic acid, or valeric acid. When compounds of formula 1 contain an acidic moiety such as a carboxylic acid, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine, or ammonia, or amides, hydrides, hydroxides, or carbonates of sodium, potassium, lithium, calcium, magnesium, or barium. Thus, the present invention includes compounds selected from formula 1, their N-oxides, and agronomically suitable salts.
[0047] Compounds selected from Formula 1, their stereoisomers, N-oxides, and salts typically exist in more than one form, and thus Formula 1 includes all crystalline and non-crystalline forms of the compounds represented by Formula 1. Non-crystalline forms include embodiments that are solids, such as waxes and gums, as well as liquids, such as solutions and melts. Crystalline forms include embodiments that represent essentially a single crystalline form and embodiments that represent mixtures of polymorphs (i.e., different crystalline forms). The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and / or conformations of the molecules in the crystal lattice. Polymorphs may have the same chemical composition, but they may also differ in composition due to the presence or absence of co-crystallized water or other molecules, which may be weakly or strongly bound in the lattice. Polymorphs may differ in chemical, physical, and biological properties, such as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspendability, dissolution rate, and bioavailability. It will be appreciated by those skilled in the art that a polymorph of a compound represented by formula I may exhibit beneficial effects (e.g., suitability for the manufacture of useful formulations, improved biological performance) compared to another polymorph or mixture of polymorphs of the same compound represented by formula I. The preparation and isolation of a particular polymorph of a compound represented by formula I can be accomplished by methods known to those skilled in the art, including, for example, crystallization using a selected solvent and temperature.
[0048] Embodiments of the invention described in the Summary of the Invention include those described below. In the following embodiments, Formula 1 includes its stereoisomers, N-oxides and salts, and is References to a "compound of Formula 1" include the definitions of the substituents specified in the Summary of the Invention, unless further defined in the embodiments.
[0049] Embodiment 1. A compound of formula 1, wherein A is A-1, A-3, or A-4.
[0050] Embodiment 1a. The compound of embodiment 1, wherein A is A-1 or A-3.
[0051] Embodiment 2. The compound of embodiment 1, wherein A is A-1.
[0052] Embodiment 3. The compound of embodiment 1, wherein A is A-3.
[0053] Embodiment 4. The compound of embodiment 1, wherein A is A-4.
[0054] Embodiment 5. A compound of Formula 1, wherein A is A-2.
[0055] Embodiment 6. Q is CR 6 The compound of formula 1 or any one of embodiments 1-5,
[0056] Embodiment 7. A compound of Formula 1 or any one of Embodiments 1-5, wherein Q is N.
[0057] Embodiment 8. Y is CR 7a R 7b or O.
[0058] EMBODIMENT 9. Y is CR 7a R 7b or NR 8 The compound of formula 1 or any one of embodiments 1-7,
[0059] Embodiment 10. Y is CR 7a R 7b The compound of embodiment 8 or 9, wherein
[0060] Embodiment 11 The compound of embodiment 8, wherein Y is O.
[0061] Embodiment 12. Y is NR 8 The compound of embodiment 9, wherein
[0062] Embodiment 13. A compound of Formula 1 or any one of Embodiments 1-12, wherein W is O.
[0063] Embodiment 14. A compound of Formula 1 or any one of Embodiments 1-12, wherein W is S.
[0064] Embodiment 15. R 1 and R 2 each independently represents halogen, cyano, hydroxy, nitro, amino, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C2-C4 cyanoalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C4-C6 cycloalkylalkyl, C2-C4 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C4 alkenyloxy, C2-C4 halo The compound of Formula 1 or any one of Embodiments 1-14, which is alkenyloxy, C2-C4 alkynyloxy, C2-C4 haloalkynyloxy, C2-C4 cyanoalkoxy, C3-C6 cycloalkoxy, C4-C6 cycloalkylalkoxy, C2-C4 alkoxyalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C3 alkylsulfinyl, C1-C3 haloalkylsulfinyl, C1-C3 alkylsulfonyl or C1-C3 haloalkylsulfonyl.
[0065] Embodiment 16. R 1 and R 2 each independently represents halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, The compound of embodiment 15, which is C2-C4 cyanoalkyl, C2-C4 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, C2-C4 cyanoalkoxy, C2-C4 alkoxyalkoxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C3 alkylsulfinyl, C1-C3 haloalkylsulfinyl, C1-C3 alkylsulfonyl or C1-C3 haloalkylsulfonyl.
[0066] Embodiment 17. R 1 and R2 are each independently halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, C2-C4 alkoxyalkoxy, or C1-C3 alkylthio.
[0067] Embodiment 18. R 1 and R 2 are each independently halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or C1-C3 alkylthio.
[0068] Embodiment 19. R 1 and R 2 and R is independently selected from the group consisting of halogen, cyano, methyl, halomethyl, methoxy, and halomethoxy.
[0069] Embodiment 20. R 1 and R 2 is each independently Br, Cl, F, methyl, trifluoromethyl, methoxy, or trifluoromethoxy.
[0070] Embodiment 21. R 1 and R 2 21. The compound of embodiment 20, wherein each is independently Cl, F or methyl.
[0071] Embodiment 22. R 1 and R 2 and R is independently Cl or F.
[0072] Embodiment 23. R 1 and R 2 and n is F.
[0073] Embodiment 24. R 3is H, C1-C3 alkyl, C2-C4 alkylcarbonyl, or C2-C4 alkoxycarbonyl.
[0074] Embodiment 25. R 3 25. The compound of embodiment 24, wherein is H, methyl, methylcarbonyl, or methoxycarbonyl.
[0075] Embodiment 26. R 3 is H or methyl.
[0076] Embodiment 27. R 3 is H.
[0077] Embodiment 28. R 4 A compound of Formula 1 or any one of Embodiments 1-27, wherein is methyl, methoxy, ethoxy, methylamino, or dimethylamino.
[0078] Embodiment 29. R 4 29. The compound of embodiment 28, wherein is methyl, methoxy, or ethoxy.
[0079] Embodiment 30. R 4 The compound of embodiment 29, wherein is methoxy.
[0080] Embodiment 31. Each R 5 is independently halogen, cyano, methyl, or methoxy.
[0081] Embodiment 32. Each R 5 32. The compound of embodiment 31, wherein is independently halogen or methyl.
[0082] Embodiment 33. Each R 5 The compound of embodiment 32, wherein is methyl.
[0083] Embodiment 34. A compound of Formula 1 or any one of Embodiments 1-33, wherein n is 0 or 1.
[0084] Embodiment 35. The compound of embodiment 34, wherein n is 0.
[0085] Embodiment 36. R 6 is H, halogen, nitro, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, -ZC(=O)V, CR 10a =NOR 10b , ON=CR 11a R 11b , C.R. 12a =NNR 12b R 12c or -LJ.
[0086] Embodiment 37. R 6 is H, halogen, nitro, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, -ZC(=O)V, CR 10a =NOR 10b , C.R. 12a =NNR 12b R 12c or -LJ.
[0087] Embodiment 38. R 6 is H, halogen, nitro, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, CR 10a =NOR 10b or -LJ.
[0088] Embodiment 39. R 6 is H, halogen, amino, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, CR 10a =NOR 10b or -LJ.
[0089] Embodiment 40. R 6 is H, halogen, amino, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, CR 10a =NOR 10b or -LJ.
[0090] Embodiment 40a.R 6 The compound of embodiment 40, wherein is H, Br, Cl, I, amino, methyl, i-propyl, trifluoromethyl, CH2F, CHF2, methoxy, ethoxy, i-propyloxy, trifluoromethoxy, CH2FO, CHF2O, CH=NOCH3, CH=NOCH2CH3.
[0091] Embodiment 41. R 6Compounds of embodiment 40a, wherein is H, Br, Cl, I, amino, methyl, i-propyl, trifluoromethyl, CHF2, methoxy, ethoxy, i-propyloxy, trifluoromethoxy, CHF2O, CH=NOCH3, CH=NOCH2CH3, C(CH3)=NOCH3, or -LJ.
[0092] Embodiment 41a.R 6 A compound of embodiment 41, wherein is H, Br, Cl, I, amino, methoxy, ethoxy, i-propyloxy, trifluoromethoxy, CHF2O, C(CH3)=NOCH3, or -LJ.
[0093] Embodiment 42. R 6 A compound of embodiment 41, wherein is H, Br, Cl, I, amino, methoxy, ethoxy, i-propyloxy, trifluoromethoxy, C(CH3)=NOCH3, or -LJ.
[0094] Embodiment 43. R 6 A compound of embodiment 42, wherein is H, Br, Cl, amino, methoxy, ethoxy, or i-propyloxy.
[0095] Embodiment 44. R 6 A compound of embodiment 43, wherein is H, Br, Cl, amino, or methoxy.
[0096] Embodiment 45. R 7a A compound of Formula 1 or any one of Embodiments 1-44, wherein is H, hydroxy, halogen, cyano, methyl, halomethyl, methoxy, or halomethoxy.
[0097] Embodiment 46. R 7a A compound of embodiment 45, wherein is H, halogen, methyl or methoxy.
[0098] Embodiment 47. R 7a is H or methyl.
[0099] Embodiment 48. R 7ais H.
[0100] Embodiment 49. R 7b A compound of Formula 1 or any one of Embodiments 1-48, wherein is H, methyl, halomethyl, methoxy, or halomethoxy.
[0101] Embodiment 50. R 7b is H, methyl or methoxy.
[0102] Embodiment 51. R 7b is H or methyl.
[0103] Embodiment 52. R 7b is H.
[0104] Embodiment 53. R 8 A compound of Formula 1 or any one of Embodiments 1-44, wherein is H, methyl, halomethyl, or methylcarbonyl.
[0105] Embodiment 54. R 8 is H or methyl.
[0106] Embodiment 55. R 8 is H.
[0107] Embodiment 56. A compound of Formula 1 or any one of Embodiments 1-55, wherein Z is a direct bond, O, NH, CH2, or CH(OCH3).
[0108] Embodiment 57. The compound of embodiment 56, wherein Z is a direct bond, O, or CH2.
[0109] Embodiment 58 The compound of embodiment 57, wherein Z is a direct bond.
[0110] Embodiment 59. The compound of embodiment 57, wherein Z is O.
[0111] Embodiment 59a. The compound of embodiment 57, wherein Z is CH2.
[0112] Embodiment 60. R 9 , R 10b , R 11a and R 12c A compound of Formula 1 or any one of Embodiments 1-59a, wherein each is H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, or C2-C4 alkynyl.
[0113] 61. R 9 , R 10b , R 11a and R 12c The compound of embodiment 60, wherein each is H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, or C2-C4 haloalkenyl.
[0114] 62. R 9 , R 10b , R 11a and R 12c The compound of embodiment 61, wherein each is H, methyl, ethyl, or C2-C4 alkenyl.
[0115] 63. R 9 , R 10b , R 11a and R 12c The compound of embodiment 62, wherein each is H or methyl.
[0116] 64. R 9 , R 10b , R 11a and R 12c and R is H.
[0117] 65. R 9 , R 10b , R 11a and R 12c and R is 1 or 2. The compound of embodiment 63, wherein each is methyl.
[0118] 66. R 10a , R 11b , R 12a and R 12b A compound of Formula 1 or any one of Embodiments 1-65, wherein each is independently H, methyl, or halomethyl.
[0119] 67. R 10a , R 11b , R 12a and R 12b and R is independently H or methyl.
[0120] 68. R 10a , R 11b , R 12a and R 12b and R is H.
[0121] 69. R 10a , R 11b , R 12a and R 12b and R is 0, R is 1, and R is 2. The compound of embodiment 68, wherein each is methyl.
[0122] Embodiment 70. L is a direct bond, CH2, O, S, NR 13 , OCH2, CH2O, or C(=O).
[0123] Embodiment 71. A compound of embodiment 70, wherein L is a direct bond, CH2, O, OCH2, CH2O, or C(=O).
[0124] Embodiment 72. A compound of embodiment 71, wherein L is a direct bond, CH2, O, OCH2, or CH2O.
[0125] Embodiment 73. A compound of embodiment 72, wherein L is a direct bond, O, or OCH2.
[0126] Embodiment 74. The compound of embodiment 72, wherein L is a direct bond.
[0127] Embodiment 75. The compound of embodiment 72, wherein L is CH2.
[0128] Embodiment 76 The compound of embodiment 72, wherein L is O.
[0129] Embodiment 77. The compound of embodiment 72, wherein L is OCH2 or CH2O.
[0130] Embodiment 78. A compound of Formula 1 or any one of Embodiments 1 to 797, wherein J is selected from J-1 to J-71 as shown in Appendix A.
[0131] Appendix A [ka] [ka] [ka] [ka] wherein the floating bond is connected to L through any available carbon or nitrogen atom of the depicted ring; and x is 0, 1, 2, or 3.
[0132] Embodiment 79. The compound of embodiment 78, wherein J is J-4, J-5, J-6, J-7, J-8, J-9, J-18, J-19, J-20, J-21, J-22, J-23, J-24, J-25, J-26, J-27, J-34, J-35, J-36, J-37, J-38, J-56, J-57, J-58, J-59, J-60, J-61, J-63, J-64, J-65, J-66, J-67, J-69, or J-70.
[0133] Embodiment 80. The compound of embodiment 79, wherein J is J-4, J-5, J-6, J-22, J-23, J-24, J-35, J-36, J-37, J-38, J-57, J-58, J-63, J-64, J-65, J-66, J-67, J-69, or J-70.
[0134] Embodiment 81. The compound of embodiment 80, wherein J is J-6, J-22, J-35, J-37, J-58, J-64, J-65, J-66, J-67, J-69 or J-70.
[0135] Embodiment 82. The compound of embodiment 81, wherein J is J-35.
[0136] Embodiment 83. The compound of embodiment 81, wherein J is J-58.
[0137] Embodiment 84. The compound of embodiment 81, wherein J is J-66.
[0138] Embodiment 85. The compound of embodiment 81, wherein J is J-67.
[0139] Embodiment 86 The compound of embodiment 81, wherein J is J-69.
[0140] Embodiment 87. The compound of embodiment 81, wherein J is J-70.
[0141] Embodiment 88. The compound of embodiment 81, wherein J is J-65, J-66, or J-67.
[0142] Embodiment 88a. The compound of embodiment 88, wherein J is J-66 or J-67.
[0143] Embodiment 89. The compound of any one of embodiments 78-88a, wherein x is 0, 1 or 2.
[0144] Embodiment 89a. The compound of embodiment 89, wherein x is 0 or 1.
[0145] Embodiment 90. The compound of any one of embodiments 89 or 89a, wherein x is 0.
[0146] 91. Each R 14are independently halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, or C(=O)OR 15 The compound of formula 1 or any one of embodiments 1-89, wherein
[0147] 92. Each R 14 are independently halogen, cyano, methyl, halomethyl, methoxy, halomethoxy, or C(=O)OR 15 92. The compound of embodiment 91, wherein
[0148] 93. Each R 14 are independently halogen, methyl, methoxy or C(=O)OR 15 93. The compound of embodiment 92, wherein
[0149] 94. Each R 14 are independently halogen, methyl or C(=O)OR 15 94. The compound of embodiment 93, wherein
[0150] 95. Each R 14 95. The compound of embodiment 94, wherein is independently halogen or methyl.
[0151] Embodiment 95a. Each R 14 96. The compound of embodiment 95, wherein is independently Br, Cl, F or methyl.
[0152] 96. Each R 15 is independently C1-C3 alkyl, C1-C3 haloalkyl, or cyclopropyl.
[0153] 97. Each R 15 is independently C1-C3 alkyl or C1-C3 haloalkyl.
[0154] 98. Each R 15 98. The compound of embodiment 97, wherein is independently methyl or ethyl.
[0155] 99. Each R 15 is methyl.
[0156] The embodiments of the present invention, including the above embodiments 1-99 as well as any other embodiments described herein, may be combined in any manner, and the descriptions of variables in the embodiments relate not only to compounds of Formula 1, but also to starting compounds and intermediate compounds useful for making compounds of Formula 1. Furthermore, the embodiments of the present invention, including the above embodiments 1-99 as well as any other embodiments described herein, and any combination thereof, relate to the compositions and methods of the present invention.
[0157] Combinations of embodiments 1 to 99 are exemplified by the following: Embodiment A. wherein: A is A-1, A-3 or A-4; Q is CR 6 and; Y is CR 7a CR 7b and; W is O; R 1 and R 2 are each independently halogen, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, C2-C4 alkoxyalkoxy, or C1-C3 alkylthio; R 3 is H, methyl, methylcarbonyl or methoxycarbonyl; R 4 is methyl, methoxy, ethoxy, methylamino or dimethylamino; Each R 5 are independently halogen or methyl; R 6is H, halogen, nitro, amino, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, -ZC(=O)V, CR 10a =NOR 10b , C.R. 12a =NNR 12b R 12c or -LJ; R 7a is H, halogen, methyl or methoxy; R 7b is H or methyl; Z is a direct bond, O, NH, CH2, or CH(OCH3); R 9 , R 10b and R 12c are each H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, or C2-C4 haloalkenyl; R 10a , R 12a and R 12b are each independently H, methyl, or halomethyl; L is a direct bond, CH2, O, OCH2, or CH2O;
[0158] J is J-1 to J-71 [ka] [ka] [ka] is selected from wherein the floating bond is connected to L through any available carbon or nitrogen atom of the depicted ring; and x is 0, 1, 2, or 3; Each R 14 are independently halogen, methyl, methoxy or C(=O)OR 15 and Each R 15 is independently C1-C3 alkyl, C1-C3 haloalkyl or cyclopropyl; A compound of formula 1.
[0159] Embodiment B. wherein: A is A-1; R 1 and R 2 are each independently Br, Cl, F, methyl, trifluoromethyl, methoxy, or trifluoromethoxy; R 3 is H or methyl; R 4 is methyl, methoxy or ethoxy; Each R 5 is methyl; R 6 is H, halogen, amino, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, CR 10a =NOR 10b or -LJ; R 7a is H or methyl; R 7b is H or methyl; R 10b is H, methyl, C2-C4 alkenyl or C2-C4 haloalkenyl; R 10a is H or methyl; L is a direct bond, O or OCH2; J is J-6, J-22, J-35, J-37, J-58, J-64, J-65, J-66, J-67, J-69, or J-70; and Each R 14 is independently halogen or methyl; A compound of embodiment A.
[0160] Embodiment C. wherein: R 1 and R 2 are each independently Cl, F or methyl; R 3 is H; R 4 is methoxy; n is 0; R 6 is H, Br, Cl, I, amino, methyl, i-propyl, trifluoromethyl, CH2F, CHF2, methoxy, ethoxy, i-propyloxy, trifluoromethoxy, CH2FO, CHF2O, CH=NOCH3, CH=NOCH2CH3, C(CH3)=NOCH3 or -LJ; R 7a is H; R 7b is H; and J is J-65, J-66 or J-67; A compound of embodiment B.
[0161] Embodiment D. wherein: R 1 and R 2 are each independently Cl or F; R 6 is H, Br, Cl, I, amino, methoxy, ethoxy, i-propyloxy, trifluoromethoxy, CHF2O, C(CH3)=NOCH3 or -LJ; J is J-66 or J-67; x is 0, 1 or 2; and R 14 is Br, Cl, F or methyl; A compound of embodiment C.
[0162] Embodiment E. wherein: R 1 and R 2 are F, respectively; and R 6is H, Br, Cl, amino, methoxy, ethoxy or i-propyloxy; A compound of embodiment D.
[0163] Specific embodiments include: Methyl N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 1); Methyl N-[[5-[1-(2,6-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 3); Methyl N-[[5-[1-(2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 4); Methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 5); Methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 6); Methyl N-[[5-[1-(4-bromo-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 7); Methyl N-[[5-[1-(2,6-difluoro-4-iodophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 8); Methyl N-[[5-[1-(2,6-difluoro-4-hydroxyphenyl)-1H-pyrazol-3-yl]-2-methyl-phenyl]methyl]carbamate (compound 10); Methyl N-[[5-[1-(4-ethoxy-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 11); Methyl N-[[5-[1-[4-(cyclobutyloxy)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 13); Methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethoxy)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 14); Methyl N-[[5-[1-[4-(difluoromethoxy)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 15); Methyl N-[[5-[1-[2,6-difluoro-4-(2-propyn-1-yloxy)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 30); Methyl N-[[5-[1-(2,6-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 33); Methyl N-[[5-[1-(4-cyclopropyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 41); Methyl N-[[5-[1-[4-[(1,1-dimethylethyl)thio]-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 42); Methyl N-[[5-[1-[4-[(difluoromethyl)thio]-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 43); Methyl N-[[5-[1-(4-ethynyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 53); Methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 63); Methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 64); Methyl N-[[5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 65); Methyl N-[[5-[1-[4-(cyclopropyloxy)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 66); Methyl N-[[5-[1-(2,6-difluoro-4-formylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 67); Methyl N-[[5-[1-(4-acetyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 68); Methyl 3,5-difluoro-4-[3-[3-[[(methoxycarbonyl)amino]methyl]-4-methylphenyl]-1H-pyrazol-1-yl]benzoate (compound 70); Methyl N-[[5-[1-[2,6-difluoro-4-(hydroxymethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 71); Methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 78); Methyl N-[[5-[1-[2,6-difluoro-4-[1-(methoxyimino)ethyl]phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 83); Methyl N-[[5-[1-[4-(difluoromethyl)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 87); Methyl N-[[5-[2-[2,6-difluoro-4-(1-methylethyl)phenyl]-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 108); Methyl N-[[5-[2-(4-amino-2,6-difluorophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 115); Methyl N-[[5-[2-(4-chloro-2,6-difluorophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 117); Methyl N-[[5-[2-(2,6-difluoro-4-nitrophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 118); Methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 121); Methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 131); and Methyl N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 132) The compound of formula 1 is selected from the group consisting of:
[0164] The present invention provides a fungicidal composition comprising a compound of formula 1 (including all stereoisomers, N-oxides, and salts thereof) and at least one other fungicide. Of particular note are compositions comprising a compound corresponding to any of the above compound embodiments.
[0165] The present invention provides a germicidal composition comprising a compound of formula 1 (including all stereoisomers, N-oxides, and salts thereof) (i.e., in a germicidal effective amount) and at least one additional component selected from the group consisting of surfactants, solid diluents, and liquid diluents. Of note among the embodiments of this composition are those which comprise a compound corresponding to any of the compound embodiments described above.
[0166] The present invention provides a method for controlling plant diseases caused by fungal plant pathogens, comprising applying to a plant or part thereof, or to the seeds of a plant, a fungicidally effective amount of a compound of formula 1, including all stereoisomers, N-oxides, and salts thereof. Of note as an embodiment of this method is a method comprising applying a fungicidally effective amount of a compound corresponding to any of the compound embodiments described above. Of particular note are embodiments in which the compound is applied as a composition of the invention.
[0167] Compounds of formula 1 can be prepared using one or more of the following methods and variations described in Schemes 1-12. 1 , R 2 , R 3 , R 4 , R 5 The definitions of , W, Y and n are as defined above in the Summary of the Invention unless otherwise indicated. The compounds of Formulae 1a-1e are a subset of Formula 1, and all substituents for Formulae 1a-1e are as defined above for Formula 1 unless otherwise indicated.
[0168] As shown in Scheme 1, compounds of formula 1 can be prepared by reacting compounds of formula 2 with compounds of formula 3 under copper or palladium catalyzed cross-coupling conditions. For compounds of formula 3 where X is a halogen or triflate, Ullmann or Buchwald-Hartwig conditions can be used. For relevant references, see, for example, Chemical Reviews 2002, 102(5), 1359-1470; Angew. Chem. Int. Ed. Engl. 2008, 47(34), 6338-6361; and Chem. Sci. 2010, 1(1), 13-31; and PCT International Publication WO2014 / 066120. This Example 1 also illustrates the method of Scheme 1. These reactions typically require the presence of a base, e.g., a metal carbonate such as potassium carbonate, and a suitable catalyst and ligand, e.g., copper(I) iodide and trans-1,2-diamino-N,N'-dimethylcyclohexane. The reactions are generally carried out in aprotic solvents such as dioxane or toluene at temperatures between ambient temperature and the boiling point of the solvent. When the compound of formula 3 is provided with an electron-withdrawing substituent (e.g., R 1 , R 2 and / or R 6 When the aryl group of the aryl group contains a aryl group (wherein is nitro, cyano, or ester) and X is a halogen, direct nucleophilic substitution of X with a compound of formula 2 can be achieved. These reactions are carried out in the presence of a base such as an alkali metal carbonate, a hydride, an alkoxide, or a trialkylamine at a temperature between about ambient temperature and 130° C. in a solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dioxane, tetrahydrofuran, or acetonitrile. For reaction conditions, see Bioorganic & Medicinal Chemistry Letters 2014, 24(24), 5805-5813; Bioorganic & Medicinal Chemistry Letters 2014, 24(24), 5805-5813; See Chemistry Letters 2010, 20(15), 4521-4525; and Journal of Materials Chemistry A: Materials for Energy and Sustainability 2014, 2(21), 7917-7926; and PCT International Publication WO2016 / 187667. Examples 2, 7, 11, and 17 (Step A) also illustrate the preparation of compounds of formula 1 by direct nucleophilic substitution. For compounds of formula 3 where X is a boronic acid, N-ram conditions can be used. These reactions are carried out in the presence of a suitable base, such as pyridine or triethylamine, and a catalyst, such as copper(II) acetate. Typically, the reactions are carried out in aprotic solvents, such as dichloromethane or chloroform, at temperatures between about ambient temperature and the boiling point of the solvent, and in the presence of oxygen. For main references, see, for example, Tetrahedron 2018, 74(5), 606-617; and Tetrahedron Lett.1998, 39(19), 2933-2936.
[0169] Scheme 1 [ka]
[0170] Compounds of formula 3 are widely available from commercial sources and can be readily prepared using commercially available precursors and known methods (see, e.g., US2013 / 0158004 and WO2018 / 011094).
[0171] In some cases, the method of scheme 1 produces two positional isomers. For example, as shown in scheme 2, the reaction of a compound of formula 2a (i.e., formula 2 where A is A-3) with a compound of formula 3 typically produces an isomeric mixture of a compound of formula 1a (i.e., formula 1 where A is A-3) and a compound of formula 1b (i.e., formula 1 where A is A-4). Purification of positional isomers can be achieved using standard techniques such as column chromatography. For related references, see, for example, PCT International Publication WO2009 / 013211. The method of scheme 2 is also illustrated in Example 18, step F.
[0172] Scheme 2 [ka]
[0173] As shown in Scheme 3, compounds of formula 2a can be prepared by reacting an alkyne of formula 4 with a suitable source of azide ion in the presence of a copper(I) salt. Suitable azide sources include, for example, trimethylsilyl azide and sodium azide. Suitable copper(I) salts include copper(I) iodide, copper(I) bromide, and copper(I) chloride. Alternatively, copper(II) salts can be combined with a mild reducing agent, for example, copper(II) sulfate with sodium ascorbate. The reaction is typically carried out in a solvent such as N,N-dimethylformamide, tetrahydrofuran, methanol, tert-butanol, dimethylsulfoxide (optionally with water), at a temperature of about 25-100°C. The use of a low boiling point solvent may in some cases require increased pressure to facilitate carrying out the reaction at a temperature above the normal boiling point of the solvent. For major references, see, for example, Organic Letters 2009, 11(23), 5490-5493; European J.Organic Chem. 2004, (18), 3789-3791; Synlett 2005, (19), 2941-2947; and Tetrahedron Letters 2006, 47(18), 3035-3038; and PCT International Publication No. WO 2004 / 072243. The method of Scheme 3 is also exemplified in this Example 18, Step E.
[0174] Scheme 3 [ka]
[0175] As shown below in Scheme 4, Method A, compounds of formula 4 can be prepared from compounds of formula 5 and alkynes of formula 6 using Sonogashira reaction coupling conditions. Sonogashira coupling is well known in the literature. See, for example, Molecules 2010, 15, 9157-9173; Sonogashira, K. In Handbook of Organopalladium Chemistry for Organic Synthesis; Negishi, E., Ed.; Wiley-Interscience: New New York, 2002, pp 493-529; Palladium in Heterocyclic Chemistry, A Guide for the Synthetic Chemist, Li, J.; Gribble, G., Eds. in Tetrahedron Organic Series, Volume 20; Pergamon Press: New York, 2000.
[0176] As shown in Scheme 4, Method B, compounds of formula 4 can be prepared by reacting compounds of formula 5 with ethynyltrimethylsilane (formula 7) in the presence of a suitable palladium catalyst (e.g., tetrakis(triphenylphosphine)palladium or dichlorobis(triphenylphosphine)palladium(II) and a suitable copper catalyst (copper(I) iodide as described above). The reaction is preferably carried out in the presence of an amine base, such as triethylamine, N,N-diisopropylethylamine, diethylamine or piperidine. The reaction is typically carried out in tetrahydrofuran, toluene or N,N-dimethylformamide. In some cases, the reaction is carried out in a solvent such as ethynyltrimethylsilane; however, in some cases, the reaction may be carried out without any solvent other than the compound of formula 5, ethynyltrimethylsilane, and an amine base. Removal of the trimethylsilane group to give the compound of formula 4 can be carried out using well-known conditions such as treatment with an alkali metal hydroxide or carbonate, such as potassium hydroxide, sodium hydroxide, or potassium carbonate, in methanol or ethanol. The reaction is preferably carried out in a suitable organic solvent. Typically, the method is most satisfactorily carried out at temperatures ranging from about 0° C. to the reflux temperature of the solvent. For representative procedures, see JACS 2003, 125(38), 11545-11552 and Bioorganic & Medicinal Chemistry 2009, 17(24), 8149-8160; and this Example 18, Steps A and B.
[0177] Scheme 4 [ka]
[0178] As shown in Scheme 5, compounds of formula 2 can be prepared by Suzuki coupling of compounds of formula 5 with boron intermediates of formula 8, where A (i.e., A-1, A-2, A-3, or A-4) is bonded to boron via a carbon atom ring member and is unsubstituted on the N atom ring member (i.e., A is a 5-membered heteroaromatic ring containing -(NH)- and -(CB(OH)2)-) ring members. This reaction is carried out in the presence of a Pd(0) or Pd(II) salt, a suitable ligand, and a base. Suitable bases for this transformation are potassium carbonate or cesium carbonate, while Pd(II) salts such as Pd(OAc)2 or PdCl2 are used in combination with ligands such as triphenylphosphine or 1,1'-bis(diphenylphosphino)ferrocene (dppf). Conditions for Suzuki coupling are well documented in the literature; see, for example, Angewandte Chemie International Edition 2006, 45(21), 3484-3488 and Tetrahedron Letters 2002, 43(16), 2885-2888. The boron intermediates of formula 8 are commercially available and can be prepared from the corresponding halides or trifluorosulfonates by methods known in the literature; see, for example, PCT International Publication No. WO2007 / 043278; U.S. Patent No. 8,080,566; Organic Letters 2011, 13(6), 1366-1369; European Journal of Medicinal Chemistry 2014, 87, 529-539 and Organic Letters 2012, 14(2), 600-603.
[0179] Other coupling procedures offer numerous alternatives for the introduction of the heterocyclic A ring on formula 5, including the coupling methods published by Heck, Stille and Kumada. Also see, for example, Zificsak et al., Tetrahedron See also 2004, 60, 8991-9016.
[0180] Scheme 5 [ka]
[0181] As shown in Scheme 6, a compound of formula 5 can be prepared by reacting an amine of formula 9 with an acid chloride of formula 10 in the presence of a base such as potassium carbonate, triethylamine, or pyridine. The reaction can be carried out neat or in a solvent such as acetonitrile, dichloromethane, chloroform, diethyl ether, or tetrahydrofuran, except for the compounds of formula 9, 10, and a base, at a temperature ranging from about 0 to 50° C. For reaction conditions, see, for example, PCT International Publication No. WO2004 / 037770 and European Patent No. EP1586552. The method of Scheme 6 is also exemplified in this Example 18, Step D.
[0182] For the synthesis of compounds of formula 10, see Advanced Organic Synthesis, 4th Edition, Wiley & Sons 1992, 437, and references cited therein. Compounds of formula 9 are commercially available or can be readily synthesized by standard methods known to those skilled in the art.
[0183] Scheme 6 [ka]
[0184] As shown in Scheme 7, compounds of formula 1 can be prepared from compounds of formula 11 by reaction with acid chlorides of formula 10, similar to the method of Scheme 6. The method of Scheme 7 is exemplified in Example 17, Step F herein.
[0185] Scheme 7 [ka]
[0186] As shown in Scheme 8, compounds of formula 11 can be prepared from nitriles of formula 12 using a suitable reducing agent such as lithium aluminum hydride or borane / tetrahydrofuran complex or tris(pentafluorophenyl)borane in an aprotic solvent such as tetrahydrofuran at a temperature between ambient temperature and the boiling point of the solvent. For relevant examples, see the procedures and references contained within PCT International Publication Nos. WO2011 / 079102 and WO2011 / 073444. The method of Scheme 8 is also exemplified in Example 17, Step E herein.
[0187] Nitriles of formula 12 can also be converted to amines of formula 11 by catalytic hydrogenation. These reactions are traditionally carried out in the presence of transition metals such as palladium(0) on carbon, Raney nickel, or platinum oxide in lower alcohol solvents such as methanol or ethanol at temperatures between ambient and 100° C. under a hydrogen gas atmosphere at pressures between 1 and 7500 kPa. For relevant examples, see the procedures and references contained within PCT Patent Application Publications WO2009 / 152868 and WO2010 / 023161.
[0188] Scheme 8 [ka]
[0189] As shown in Scheme 9, a compound of formula 12 can be prepared by coupling a compound of formula 13, where A (i.e., A-1, A-2, A-3, or A-4) is unsubstituted at the N atom ring member (i.e., A is a 5-membered heteroaromatic ring containing the ring member -(NH)-), with a compound of formula 3 using a method similar to Scheme 1. Example 17, Step A herein illustrates the method of Scheme 9.
[0190] Scheme 9 [ka]
[0191] As shown in Scheme 10, a compound of formula 13 can be prepared from a compound of formula 14. In a typical procedure, a compound of formula 14 is contacted with a cyanide salt, such as copper(I) cyanide or zinc(II) cyanide, in the presence of a suitable transition metal catalyst, such as copper(I) iodide or tetrakis(triphenylphosphine)palladium(0), in a polar aprotic solvent, such as N,N-dimethylformamide or dimethylsulfoxide, at a temperature between about 50-150° C. For related procedures, see PCT Patent Application Publications WO2012 / 032528 and WO2011 / 133882 and the references contained therein.
[0192] Scheme 10 [ka]
[0193] As shown in Scheme 11, compounds of formula 14 can be prepared by first reacting a compound of formula 15 with N,N-dimethylformamide dimethylacetal (DMF-DMA) in a solvent such as toluene or benzene at a temperature between about 40-100° C. to give an intermediate compound of formula 16. In a subsequent step, the compound of formula 16 is reacted with hydrazine or a hydrazine salt in a lower alcohol solvent such as methanol or ethanol to give a compound of formula 14.
[0194] Scheme 11 [ka]
[0195] The compounds of formula 1 described herein and intermediates thereto can be subjected to a variety of electrophilic, nucleophilic, organometallic, oxidation and reduction reactions to add or modify existing substituents, thereby affording other functionalized compounds of formula 1. For example, as shown in Scheme 13, compounds of formula 1c (i.e., where Q is CR 6 and R 6 Formula 1, where Q is NH, can be prepared by the use of Fe, Zn, or SnCl in aqueous acid at temperatures ranging from ambient to reflux to give the corresponding nitro compound of formula 1e, i.e., where Q is CR 6 and R 6 In a subsequent reaction, the amino compound of formula 1c is converted to a halogen in the presence of a halogen source under diazotization conditions to give the compound of formula 1d (i.e., where Q is CR 6 and R 6 A variety of halogen sources can be used in the method of Scheme 12. The presence of a Lewis acid, such as titanium(IV) isopropoxide, can also be advantageous. For example, tert-butylnitrile is added to a solution of an amino compound of formula 1c in the presence of CuBr2 in a solvent such as acetonitrile to give the corresponding bromide compound of formula 1d. Similarly, an amino compound of formula 1c can be converted to a diazonium salt according to general procedures well known to those skilled in the art, and then reacted with a mineral acid, typically containing the same halide atom (e.g., R is I, in a solvent such as water, acetic acid, or trifluoroacetic acid). 6The compound of formula 1c can be converted to the corresponding compound of formula 1d by treatment with sodium nitrite in the presence of aqueous HI (for example, aqueous HI) followed by treatment with the corresponding copper(I) or copper(II) salt. Many known reduction, diazotization and halogenation methods can be readily adapted to prepare compounds of formula 1c and 1d, see, for example, the procedures and references contained within U.S. Patent Applications US2017 / 0121300, US2017 / 069105, and US2017 / 038909, and PCT Patent Application Publication WO2017 / 036357. The method of scheme 12 is also exemplified in Examples 3 and 4 herein.
[0196] Scheme 12 [ka]
[0197] It is recognized that some of the reagents and reaction conditions described above for preparing compounds of formula 1 may not be compatible with certain functional groups present in intermediates. In these instances, incorporating protection / deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and selection of protecting groups will be apparent to those skilled in the art of chemical synthesis (see, for example, TW Greene and PG M Huts, Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). Those skilled in the art will appreciate that in some cases, the synthesis of compounds of formula 1 can be completed after the introduction of certain reagents shown in the individual schemes. It will be appreciated that it may be necessary to carry out additional conventional synthetic steps not specifically described in order to complete the synthesis. Those skilled in the art will also appreciate that it may be necessary to carry out combinations of the steps illustrated in the above schemes in an order other than that indicated by the particular order presented to prepare compounds of formula 1.
[0198] Those skilled in the art will also appreciate that the compounds of formula 1 and intermediates described herein may be subjected to a variety of electrophilic, nucleophilic, radical, organometallic, oxidative, and reductive reactions to add substituents or modify existing substituents.
[0199] Without further elaboration, it is believed that one skilled in the art can utilize the preceding description to utilize the present invention to its fullest extent. Thus, the following examples are merely illustrative and should not be construed as limiting the present disclosure in any manner. The steps in the following examples describe the procedures for each step in the overall synthetic transformation, and the starting material for each step may not have been prepared by the specific preparation run that the procedure is described in other examples or steps. Percentages are by weight unless chromatographic solvent mixtures or otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. 1 H NMR spectra are reported in ppm downfield shifts from tetramethylsilane; "s" means singlet, "d" means doublet, "t" means triplet, "m" means multiplet, "br s" means broad singlet, and "dd" means double doublet. Mass spectra are reported in ppm downfield shifts from tetramethylsilane; "s" means singlet, "d" means doublet, "t" means triplet, "m" means multiplet, "br s" means broad singlet, and "dd" means double doublet. + The molecular weights are reported as the molecular weights of the parent ions (M+1) of highest isotopically abundance formed by the addition of a 1-membered ion (1) to a molecule of molecular weight 1, and these are analyzed by atmospheric pressure chemical ionization (APCI) using liquid chromatography coupled to a mass spectrometer (LCMS). + ) or electrospray ionization (ESI + ) are used for observation.
[0200] Example 1 Preparation of methyl N-[[5-[1-(2,6-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 3) To a mixture of methyl N-[[2-methyl-5-(1H-pyrazol-3-yl)phenyl]methyl]carbamate (1.12 g, 4.57 mmol) (see PCT International Publication WO2008124092 for preparation), copper(I) iodide (0.17 g, 0.914 mmol) and 2-bromo-1,3-difluoro-5-methoxy-benzene (1.32 g, 5.94 mmol) was added potassium carbonate (11.4 mmol) followed by N,N-dimethylformamide (8 mL). Nitrogen gas was bubbled through the reaction mixture for 30 minutes and then trans-N,N'-dimethylcyclohexane-1,2-diamine (0.26 g, 1.83 mmol) was added. The reaction mixture was heated at 80° C. overnight, cooled to room temperature and diluted with ethyl acetate. The resulting mixture was washed with saturated aqueous sodium chloride (4x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 20-80% ethyl acetate in hexanes) to give the title compound, a compound of this invention, as a colorless oil (0.43 g). 1 H NMR (CDCl3): δ 7.74(d, 1H), 7.67(dd, 1H), 7.59(d, 1H), 7.22(d, 1H), 6.74(d, 1H), 6.61(d, 2H), 4.87(br s, 1H), 4.41(d, 2H), 3.84(s, 3H), 3.69(s, 3H), 2.36(s, 3H). LCMS: m / z: 388 [M+H] +
[0201] Example 2 N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-pyrazole- Preparation of methyl 3-yl-2-methylphenylmethylcarbamate (Compound 1) To a stirred solution of methyl N-[[2-methyl-5-(1H-pyrazol-3-yl)phenyl]methyl]carbamate (0.45 g, 1.84 mmol) (see PCT International Publication WO2008124092 for preparation method) in dimethylsulfoxide (5 mL) was added potassium carbonate (762 mg, 5.52 mmol) and 1,2,3-trifluoro-5-nitrobenzene (0.235 mL, 2.02 mmol). The reaction mixture was stirred at room temperature overnight and diluted with ethyl acetate. The resulting mixture was washed with saturated aqueous sodium chloride (4x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by column chromatography (eluted with a gradient of 10-50% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as a yellow solid (0.44 g). 1 H NMR (CDCl3): δ 8.02(d, 2H), 7.79(dd, 1H), 7.75(d, 1H), 7.69(dd, 1H), 7.25(d, 1H), 6.85(d, 1H), 4.86(br s, 1H), 4.44(d, 2H), 3.71(s, 3H), 2.38(s, 3H).
[0202] Example 3 Preparation of methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 5) To a mixture of methyl N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 2) (0.4 g, 0.995 mmol) and ammonium chloride (32 mg, 0.597 mmol) in ethanol / water (9:1, 20 mL) was added iron powder (555 mg, 9.95 mmol) in portions. The reaction mixture was heated to reflux for 1.5 hours, then cooled to room temperature and filtered through a pad of Celite® (diatomaceous earth filter aid), rinsing with ethyl acetate. The filtrate was washed with saturated aqueous sodium chloride (4x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 30-100% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as a light yellow solid (0.3 g). 1 H NMR (CDCl3): δ 7.75(d, 1H), 7.66(dd, 1H), 7.56(d, 1H), 7.21(d, 1H), 6.72(d, 1H), 6.31(d, 2H), 4.82(br s, 1H), 4.41(d, 2H), 4.04(br s, 2H), 3.69(s, 3H), 2.36(s, 3H).
[0203] Example 4 Preparation of methyl N-[[5-[1-(4-bromo-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 7) To a mixture of methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 3) (90 mg, 0.242 mmol) in acetonitrile (2 mL) was added copper(II) bromide (65 mg, 0.290 mmol). The reaction mixture was cooled to about 0° C., and n-butyl nitrite (0.043 mL, 0.363 mmol) was added. The reaction mixture was stirred at room temperature overnight and then quenched with hydrochloric acid (1N aqueous solution). The resulting mixture was extracted with ethyl acetate (2×), and the combined extracts were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 10-40% ethyl acetate in hexanes). The resulting material was further purified by column chromatography (eluting with a gradient of 0-10% ethyl acetate in dichloromethane) to afford the title compound, a compound of the present invention, as a yellow oil. 1 H NMR (CDCl3): δ 7.74(d, 1H), 7.67-7.65 ( m, 2H), 7.29(d, 2H), 7.23(d, 1H), 6.78(d, 1H), 4.83(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.37(s, 3H). LCMS: m / z: 436 [M+H] +
[0204] Example 5 Preparation of methyl N-[[5-[1-(2,6-difluoro-4-hydroxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 10) To a mixture of methyl N-[[5-[1-(2,6-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 1) (1.20 g, 3.10 mmol) in dichloromethane (30 mL) at 0° C. was added boron tribromide (1 M solution in dichloromethane, 9.40 mL, 9.30 mmol) dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was slowly quenched with water (35 mL), followed by dropwise addition of methanol (35 mL) and then stirred at room temperature for 1 hour. The layers were separated and the aqueous layer was extracted with dichloromethane (2×). The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with a gradient of 20-70% ethyl acetate in hexane) to give the title compound, a compound of the present invention, as a white solid (0.87 g). 1 H NMR (CDCl3): δ 7.74(br s, 1H), 7.63(dd, 1H), 7.60(d, 1H), 7.24(d, 1H), 6.75(d, 1H), 6.46(d, 2H), 4.95(br s, 1H), 4.42(d, 2H), 3.69(s, 3H), 2.37(s, 3H).
[0205] Example 6 Preparation of methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethoxy)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 14) To a mixture of methyl N-[[5-[1-(2,6-difluoro-4-hydroxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 5) (87 mg) in tetrahydrofuran (3 mL) was added triphenylphosphine (122 mg, 0.46 mmol), followed by 2-propanol (0.035 mL, 0.46 mmol) and diethyl azodicarboxylate (0.073 mL, 0.46 mmol). The reaction mixture was stirred at room temperature for 48 hours and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 10-50% ethyl acetate in hexane) to give the title compound, a compound of the present invention, as a white solid (85 mg). 1 H NMR (CDCl3): δ 7.75(d, 1H), 7.67(dd, 1H), 7.59(d, 1H), 7.22(d, 1H), 6.74(d, 1H), 6.58(d, 2H), 4.54 (m, 1H), 4.83(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.36(s, 3H), 1.37(d, 6H). LCMS: m / z: 416 [M+H] +
[0206] Example 7 Preparation of methyl 3,5-difluoro-4-[3-[3-[[(methoxycarbonyl)amino]methyl]-4-methylphenyl]-1H-pyrazol-1-yl]benzoate (Compound 70) Methyl N-[[2-methyl-5-(1H-pyrazol-3-yl)phenyl]methyl]carbamate (2.58 g, 10.5 mmol) (the preparation method is described in the PCT International Publication To a mixture of methyl 3,4,5-trifluorobenzoate (2.41 g, 12.6 mmol) in dimethylsulfoxide (10 mL) was added potassium carbonate (4.35 g, 31.5 mmol). The reaction mixture was stirred at room temperature for 48 hours and diluted with ethyl acetate. The resulting mixture was washed with saturated aqueous ammonium chloride (4x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by column chromatography (eluted with a gradient of 10-50% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as a pale red solid (3.55 g). 1 H NMR(CDCl3): δ 7.76(d, 2H), 7.74(m, 2H), 7.68(d, 1H), 7.24(d, 1H), 6.80(d, 1H), 4.87(br s, 1H), 4.42(d, 2H), 3.97(s, 3H), 3.70(s, 3H), 2.37(s, 3H).
[0207] Example 8 Preparation of methyl N-[[5-[1-[2,6-difluoro-4-(hydroxymethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 71) To a mixture of methyl 3,5-difluoro-4-[3-[3-[[(methoxycarbonyl)amino]methyl]-4-methylphenyl]-1H-pyrazol-1-yl]benzoate (i.e., the product of Example 7) (3.55 g, 8.55 mmol) in methanol (45 mL) was added sodium borohydride (1.94 g, 51.3 mmol) in portions. The reaction mixture was stirred at room temperature overnight, then quenched with hydrochloric acid (1N aqueous solution) and filtered. The filtrate was extracted with ethyl acetate (3x), and the combined extracts were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 20-100% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as a white solid (2.52 g). 1 H NMR(DMSO-d6,): δ 8.11(d, 1H), 7.73(d, 1H), 7.65(t, 1H), 7.62(dd, 1H), 7.29(d, 1H), 7.22(d, 1H) , 6.94(d, 1H), 5.59(t, 1H), 4.60(d, 2H), 4.21(d, 2H), 3.55(s, 3H), 2.30(s, 3H).
[0208] Example 9 Preparation of methyl N-[[5-[1-(2,6-difluoro-4-formylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 67) To a mixture of methyl N-[[5-[1-[2,6-difluoro-4-(hydroxymethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 8) (2.30 g, 5.94 mmol) in tetrahydrofuran (70 mL) was added Dess-Martin periodinane (2.52 g, 5.94 mmol) in portions. The reaction mixture was stirred at room temperature overnight, then quenched with aqueous sodium carbonate and extracted with ethyl acetate (2x). The combined extracts were filtered and rinsed with ethyl acetate. The filtrate was washed with saturated aqueous sodium bicarbonate (3x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 20-60% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as a white solid (1.78 g). 1 H NMR (CDCl3): δ 9.98(t, 1H), 7.76 (m, 2H), 7.69(dd, 1H), 7.62(d, 2H), 7.24(d, 1H), 6.83(d, 1H), 4.86(br s, 1H), 4.43(d, 2H), 3.71(s, 3H), 2.38(s, 3H).
[0209] Example 10 Preparation of methyl N-[[5-[1-[4-(difluoromethyl)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 87) To a mixture of methyl N-[[5-[1-(2,6-difluoro-4-formylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 9) (0.25 g, 0.65 mmol) in dichloromethane (10 mL) at about 0° C. was added Deoxo-Fluor® (0.36 mL, 1.95 mmol) dropwise, followed by ethanol (1 drop). The reaction mixture was stirred at room temperature overnight and then slowly poured into saturated aqueous sodium carbonate (200 mL). After 30 minutes the layers were separated and the aqueous layer was extracted with dichloromethane (1x). The combined organics were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with a gradient of 10-50% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as a colorless oil (0.23 g). 1 H NMR(CDCl3): δ 7.75(d, 1H), 7.71-7.68 (m, 2H), 7.27(d, 2H), 7.23(d, 1H), 6.80(d, 1H), 6.78-6.55(t, 1H), 4.85(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.37(s, 3H). LCMS: m / z:408 [M+H] +
[0210] Example 11 Preparation of methyl N-[[5-[1-(4-acetyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 68) To a mixture of methyl N-[[2-methyl-5-(1H-pyrazol-3-yl)phenyl]methyl]carbamate (2.0 g, 8.16 mmol) (see PCT International Publication WO2008124092 for preparation method) and 1-(3,4,5-trifluorophenyl)ethanone (2.0 g, 11.4 mmol) in dimethylsulfoxide (9 mL) was added potassium carbonate (3.38 g, 24.5 mmol). The reaction mixture was stirred at room temperature overnight and then diluted with ethyl acetate. The resulting mixture was washed with saturated aqueous ammonium chloride (4x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 10-70% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as a pale orange solid (2.10 g). 1 H NMR (CDCl3): δ 7.75 (m, 2H), 7.69 (dd, 1H), 7.67 (d, 2H), 7.24 (d, 1H), 6.81 (d, 1H), 4.87 (br s, 1H), 4.43(d, 2H), 3.70(s, 3H), 2.64(s, 3H), 2.37(s, 3H).
[0211] Example 12 Preparation of methyl N-[[5-[1-[2,6-difluoro-4-[1-(methoxyimino)ethyl]phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 83) A mixture of methyl N-[[5-[1-(4-acetyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 11) (0.24 g, 0.602 mmol), O-methylhydroxylamine hydrochloride (60.3 mg, 0.722 mmol) and sodium acetate (59.2 mg, 0.722 mmol) in ethanol was heated to reflux overnight. The reaction mixture was cooled to room temperature and diluted with water. The resulting mixture was extracted with ethyl acetate (2x) and the combined extracts were dried over magnesium sulfate, filtered and concentrated under reduced pressure to give the title compound, a compound of the present invention, as an amber solid (239 mg). 1 H NMR(CDCl3): δ 7.75(d, 1H), 7.68(m, 2H), 7 .41(d, 2H), 7.23(d, 1H), 6.78(d, 1H), 4.85(br s, 1H), 4.42(d, 2H), 4.04(s, 3H), 3.70(s, 3H), 2.37(s, 3H), 2.21(s, 3H). LCMS: m / z: 429 [M+H] +
[0212] Example 13 Preparation of methyl N-[[5-[1-(2,6-difluoro-4-iodophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 8) To a mixture of methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 3) (2.38 g, 6.40 mmol) in acetonitrile (50 mL) was added diiodomethane (2.1 mL, 25.6 mmol). The reaction mixture was cooled to about 0° C., and then tert-butyl nitrite (0.84 mL, 7.04 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 5 hours, and then more diiodomethane (12 mL, 150 mmol) was added. After stirring overnight, the reaction mixture was diluted with ethyl acetate and washed with saturated sodium metabisulfite (3×), saturated sodium chloride solution (2×), and hydrochloric acid (1N aqueous solution). The mixture was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with a gradient of 0-10% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as an off-white solid (1.0 g). 1 H NMR(CDCl3): δ 7.73(d, 1H), 7.66-7.64 (m, 2H), 7.47(d, 2H), 7.22(d, 1H), 6.77(d, 1H), 4.86(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.36(s, 3H).
[0213] Example 14 Preparation of methyl N-[[5-[1-(4-ethynyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 53) Step A: Preparation of methyl N-[[5-[1-(2,6-difluorophenyl-4-(2-(trimethylsilyl)ethynyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate To a mixture of methyl N-[[5-[1-(2,6-difluoro-4-iodophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 13) (0.2 g, 0.414 mmol), copper(I) iodide (8 mg, 0.041 mmol), N,N-dimethylformamide (4 mL), ethynyltrimethylsilane (0.088 mL, 0.621 mmol) and dichlorobis(triphenylphosphine)palladium (29 mg, 0.041 mmol) was added triethylamine (0.063 mL, 0.455 mmol). The reaction mixture was stirred at room temperature overnight, then diluted with ethyl acetate, washed with saturated sodium chloride solution (4x), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 5-40% ethyl acetate in hexane) to give the title compound as a light brown oil (0.17 g). 1 H NMR (CDCl3): δ 7.74(d, 1H), 7.67 (m, 2H), 7.23(d, 1H), 7.16(d, 2H), 6.77(d, 1H), 4.84(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.37(s, 3H), 0.27(s, 9H).
[0214] Step B: Preparation of methyl N-[[5-[1-(4-ethynyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (compound 53) To a mixture of methyl N-[[5-[1-(2,6-difluorophenyl-4-(2-(trimethylsilyl)ethynyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Step A) (0.12 g, 0.265 mmol) in methanol (6 mL) was added potassium carbonate (44 mg, 0.318 mmol). The reaction mixture was stirred at room temperature for 1.5 hours, then diluted with ethyl acetate and water, and allowed to stand at room temperature overnight. The resulting mixture was washed with saturated sodium chloride solution (2x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 10-50% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as an amber oil (0.109 g). 1 H NMR (CDCl3): δ 7.75(d, 1H), 7.68-7.66(m, 2H), 7.23(d, 1H), 7.20(d, 2H), 6.78(d, 1H), 4.84(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 3.24(s, 1H), 2.37(s, 3H). LCMS m / z: 382 [M+H] +
[0215] Example 15 Preparation of methyl N-[[5-[1-[4-[(1,1-dimethylethyl)thio]-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 42) A mixture of methyl N-[[5-[1-(2,6-difluoro-4-iodophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 13) (0.217 g, 0.450 mmol) and N,N-dimethylformamide (2 mL) was purged with a stream of nitrogen for 10-15 minutes, then tetrakis(triphenylphosphine)palladium (52 mg, 0.045 mmol) was added, followed by 2-methyl-2-propanethiol (0.100 mL, 0.900 mmol) and triethylamine (0.20 mL, 1.35 mmol). The reaction mixture was heated at 70° C. for 1 hour, then cooled to room temperature and diluted with ethyl acetate. The resulting mixture was washed with saturated sodium chloride solution (3×), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with a gradient of 10-50% ethyl acetate in hexane) to give the title compound, a compound of the present invention, as an orange oil (0.189 g). 1 H NMR (CDCl3): δ 7.75(d, 1H), 7.69-7.67(m, 2H), 7.27(d, 2H), 7.23(d, 1H), 6.79(d, 1H), 4.84(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.37(s, 3H), 1.37(s, 9H).
[0216] Example 16 Preparation of methyl N-[[5-[1-[4-[(difluoromethyl)thio]-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 43) Step A: Preparation of methyl N-[[5-[1-(2,6-difluoro-4-mercaptophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate To a mixture of methyl N-[[5-[1-[4-[(1,1-dimethylethyl)thio]-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 15) (0.16 g, 0.360 mmol) in dichloromethane (5 mL) at about 0° C. was added boron tribromide (1 M solution in dichloromethane, 1.10 mL, 1.08 mmol) dropwise. The reaction mixture was stirred at room temperature overnight and quenched with water (6 mL) and methanol (6 mL). After stirring for 2 h, the layers were separated and the aqueous layer was extracted with dichloromethane (2×). The combined organics were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography. Purification by chromatography (eluting with a gradient of 20 to 100% ethyl acetate in hexane) gave the title compound as a solid (77 mg). 1 H NMR (CDCl3): δ 7.74 (d, 1H), 7.67 (dd, 1H), 7.62 (m, 1H), 7.22 (d, 1H), 6.98 (d, 2H), 6.75 (d, 1H), 4.83 (br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.36(s, 3H).
[0217] Step B: Preparation of methyl N-[[5-[1-[4-[(difluoromethyl)thio]-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate To a mixture of methyl N-[[5-[1-(2,6-difluoro-4-mercaptophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (i.e., product of step A) (77 mg, 0.198 mmol) in acetonitrile and water (1:1, 2 mL) was added potassium hydroxide (222 mg, 3.96 mmol) followed by diethyl(bromodifluoromethyl)phosphonate (0.070 mL, 0.396 mmol). The reaction mixture was stirred at room temperature for 1.5 hours and then diluted with ethyl acetate. The resulting mixture was washed with saturated sodium chloride solution (2x), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with a gradient of 10-50% ethyl acetate in hexanes) to give the title compound, a compound of the present invention, as an off-white solid (64 mg). 1 H NMR (CDCl3): δ 7.75(d, 1H), 7.70-7.68(m, 2H), 7.34(d, 2H), 7.24(d, 1H), 7.02-6.80(t, 1H), 6.80(d, 1H), 4.84(br s, 1H), 4.42(d, 2H), 3.70(s, 3H), 2.37(s, 3H). LCMS m / z: 440 [M+H] +
[0218] Example 17 Preparation of methyl N-[[5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate (Compound 65) Step A: Preparation of 5-[1-(2,6-dichloro-4-nitrophenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile A mixture of 2-methyl-5-(1H-pyrazol-3-yl)benzonitrile (3.0 g, 16.4 mmol) (see PCT International Publication WO2014066120 for preparation), 1,3-dichloro-2-fluoro-5-nitrobenzene (4.12 g, 19.6 mmol) and potassium carbonate (2.72 g, 19.6 mmol) in N,N-dimethylformamide (51 mL) was heated at 80° C. for 4 hours and then stirred at room temperature overnight. The reaction mixture was diluted with water and the resulting precipitate was collected by filtration and rinsed with water. The solid precipitate was triturated with a mixture of hexane / 1-chlorobutane, filtered and air-dried to give the title compound (3.59 g). 1 H NMR (CDCl3): δ 8.37(s, 2H), 8.11(s, 1H), 7.96(d, 1H), 7.64(s, 1H), 7.38(d, 1H), 6.87(s, 1H), 2.60(s, 3H).
[0219] Step B: Preparation of 5-[1-(4-amino-2,6-dichlorophenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile To a mixture of tin(II) chloride dihydrate (12.82 g, 56.82 mmol), acetic acid (51.78 mL), and concentrated hydrochloric acid (34.57 mL) was added 5-[1-(2,6-dichloro-4-nitrophenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile (i.e., the product of Step A) (6.07 g, 16.26 mmol), while maintaining the reaction temperature at about 25° C. 100 g) was added portionwise. The reaction mixture was stirred overnight and then slowly poured into a mixture of potassium hydroxide (200 g), water (200 g) and ice (400 g). The resulting solid precipitate was collected by filtration and dried to give the title product (6.8 g). 1 H NMR (CDCl3): δ 8.22(s, 1H), 7.98(d, 1H), 7.55(s, 1H), 7.35(d, 1H), 6.76(s, 1H), 6.71(s, 2H), 4.06(s, 2H), 2.57(s, 3H).
[0220] Step C: Preparation of 5-[1-(4-bromo-2,6-dichlorophenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile A mixture of 5-[1-(4-amino-2,6-dichlorophenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile (i.e., the product of Step B) (6.75 g, 18.67 mmol) and n-butyl nitrite (27.38 mL, 233.7 mmol) was heated to reflux overnight, then cooled to room temperature and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with 20% ethyl acetate in hexane) to give the title compound (4.3 g). 1 H NMR (CDCl3): δ 8.22(s, 1H), 7.96(d, 1H), 7.66(s, 2H), 7.58(s, 1H), 7.36(d, 1H), 6.80(s, 1H), 2.57(s, 3H).
[0221] Step D: Preparation of 5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile A mixture of 5-[1-(4-bromo-2,6-dichlorophenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile (i.e., product of step C) (2.19 g, 5.37 mmol), cyclopropylboronic acid (0.53 g, 6.31 mmol), sodium carbonate (1.99 g, 18.75 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.46 g, 0.66 mmol) in 1,2-dimethoxyethane (43.7 mL) and water (10.03 mL) was heated at 85° C. overnight. The reaction mixture was cooled to room temperature and partitioned between water and ethyl acetate. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (0-10% ethyl acetate in hexanes) to give the title compound (0.90 g). 1 H NMR(CDCl3):δ 8.13(s, 1H), 7.97(d, 1H), 7.55(s, 1H), 7.34(d, 1H), 7.15(s, 2H), 6.78(s, 1H), 2.57(s, 3H), 1.98-1.90(m, 1H), 1.14-1.08(m, 2H), 0.81-0.75(m, 2H).
[0222] Step E: Preparation of 5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylbenzenemethanamine hydrochloride To a mixture of 5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylbenzonitrile (i.e., the product of step D (0.88 g, 2.39 mmol)) in dichloromethane (5 mL) was added tris(2,3,4,5,6-pentafluorophenyl)borane (0.01 g, 0.07 mmol) followed by diethylsilane (0.53 g, 5.97 mmol). The reaction mixture was stirred at room temperature overnight, cooled to about 0-5° C., and then hydrochloric acid (4N solution in dioxane, 2.02 mL) was added dropwise. The resulting precipitate was collected by filtration and air-dried to provide the title compound as a solid (0.82 g). 1 H NMR(CDCl3):δ 8.30(br s, 3H), 8.03(s, 1H), 7.95(s, 1H), 7.77(d, 1H), 7.43(s, 2H), 7.32(d, 1H), 6.97(s, 1H), 3.57(s, 2H), 2.36(s, 3H), 2.13-2.05(m, 1H), 1.14-1.05(m, 2H), 0.91-0.85( m, 2H).
[0223] Step F: Preparation of methyl N-[[5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate To a mixture of 5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylbenzenemethanamine hydrochloride (i.e., product of step E) (0.82 g, 2.01 mmol) and potassium carbonate (0.83 g, 6.02 mmol) in acetonitrile (10 mL) at about 0-5° C., methyl chloroformate (0.21 g, 2.21 mmol) was added. The reaction mixture was stirred overnight at room temperature and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with 0%-100% ethyl acetate in hexane) to obtain the title compound, a compound of the present invention, as a solid (0.87 g). 1H NMR (CDCl3): δ 7.78(s, 1H), 7.70(d, 1H), 7.63(s, 1H), 7.22(d, 1H), 7.15(s, 2H), 6.76(s, 1H), 4.82(br s, 1H), 4.41(br s, 2H), 3.70(s, 3H), 2.37(s, 3H), 1.95-1.88(m, 1H), 1.12-1.08(m, 2H), 0.80-0.72(m, 2H). LCMS: m / z 430[M+H] +
[0224] Example 18 Preparation of methyl N-[[5-[2-(2,6-difluoro-4-nitrophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 118) and methyl N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 132) Step A: Preparation of 2-methyl-5-[2-(trimethylsilyl)ethynyl]benzonitrile To a mixture of 2-amino-5-bromobenzonitrile (50 g, 255 mmol) and ethynyltrimethylsilane (181 mL, 1275 mmol) in tetrahydrofuran (600 mL) was added bis(triphenylphosphine)palladium(II) dichloride (26 g, 38 mmol), copper(I) iodide (14.5 g, 76.5 mmol), triphenylphosphine (20 g, 76.5 mmol) and triethylamine (600 mL). The reaction mixture was stirred at room temperature for 24 hours and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with 5% ethyl acetate in petroleum ether) to give the title compound as a solid (45 g). 1 H NMR (CDCl3): δ 7.68 (d, J=1.6Hz, 1H), 7.63 (dd, J=8.0, 1.6 Hz, 1H), 7.24 (s, 1H), 2.53 (s, 3H), 0.24 (s, 9H).
[0225] Step B: Preparation of 5-ethynyl-2-methylbenzonitrile To a mixture of 2-methyl-5-[2-(trimethylsilyl)ethynyl]benzonitrile (i.e., the product of Step A) (40 g, 187.7 mmol) in methanol (800 mL) was added potassium hydroxide (67 mL, 1% in methanol). The reaction mixture was stirred at room temperature for 16 hours and then distilled to remove methanol. The resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate. The combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with 12% ethyl acetate in petroleum ether) to give the title compound as a solid (15 g). 1 H NMR(CDCl3): δ 7.70(d, J=1.2Hz, 1H), 7.57( dd, J=8.4, 2.0 Hz, 1H), 7.28(d, J=7.6 Hz, 1H), 3.12(s, 1H), 2.55(s, 3H).
[0226] Step C: Preparation of 5-ethynyl-2-methylbenzenemethanamine hydrochloride To a mixture of diphenylsilane (81 mL, 443 mmol) in chloroform (250 mL) was added tris(2,3,4,5,6-pentafluorophenyl)borane (2.7 g, 5.3 mmol) followed by 5-ethynyl-2-methylbenzonitrile (i.e., the product of step B) (25 g, 177.3 mmol) in chloroform. The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. Hydrochloric acid (2N solution in diethyl ether) was added to the resulting material and the mixture was stirred for 1 hour. The resulting solid precipitate was collected by filtration and dried to give the title compound as a solid (30 g). 1 H NMR (DMSO-d6): δ 8.26 (br s, 3H), 7.53 (s, 1H), 7.37-7.39 (m, 1H), 7.27-7.25 (m, 1H), 4.19 (s, 1H), 4.01 (s, 2H), 2.35 (s, 3H).
[0227] Step D: Preparation of methyl [(5-ethynyl-2-methylphenyl)methyl]carbamate To a mixture of 5-ethynyl-2-methylbenzenemethanamine hydrochloride (i.e., the product of Step C) (30 g, 165.7 mmol) and potassium carbonate (68.5 g, 497 mmol) in acetonitrile (330 mL) at 0° C. was added methyl chloroformate (23.3 g, 248.6 mmol) dropwise over 20 minutes. The reaction mixture was stirred at room temperature for 16 hours, then diluted with water (200 mL) and extracted with ethyl acetate. The combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by column chromatography (eluted with 30% ethyl acetate in petroleum ether) to give the title compound as a solid (25 g). 1 H NMR(CDCl3): δ 7.38(br s, 1H), 7.33-7.31(m, 1H), 7.13-7.11 (m, 1H), 4.83 (brs, 1H) 4.34 (d, J=5.6Hz, 2H), 3.71 (s, 3H), 3.04 (s, 1H), 2.32 (s, 3H).
[0228] Step E: Preparation of methyl N-[[5-(1H-1,2,3-triazol-4-yl)-2-methylphenyl]methyl]carbamate To a mixture of methyl [(5-ethynyl-2-methylphenyl)methyl]carbamate (i.e., the product of step D) (30 g, 165.7 mmol) in N,N-dimethylformamide (117 mL) was added methanol (12 mL), trimethylsilyl azide (11.7 mL, 88.6 mmol) and copper(I) iodide (0.56 g, 2.9 mmol). The reaction mixture was heated at 100° C. for 16 hours, then diluted with saturated ammonium chloride solution and extracted with ethyl acetate. The combined organic extracts were washed with water and saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluted with 20% ethyl acetate in petroleum ether) to give the title compound as a solid (4 g). 1H NMR (CDCl3): δ 11.8(br s, 1H), 7.94(s, 1H), 7.71(s, 1H), 7.64-7.61(m, 1H), 7.24(s, 1H), 4.93(br s, 1H), 4.43(d, J=6.0Hz, 2H), 3.71(s, 3H), 2.37(s, 3H).
[0229] Step F: Methyl N-[[5-[2-(2,6-difluoro-4-nitrophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 118) and N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 118) Preparation of methyl carbamate (compound 132) To a mixture of methyl N-[[5-(1H-1,2,3-triazol-4-yl)-2-methylphenyl]methyl]carbamate (i.e., product of step E) (4 g, 16.2 mmol) in dimethylsulfoxide (40 mL) was added potassium carbonate (6.7 g, 48.6 mmol) followed by 1,2,3-trifluoro-5-nitrobenzene (3.1 g, 17.8 mmol). The reaction mixture was stirred at room temperature for 16 h, then diluted with water (30 mL) and extracted with ethyl acetate. The combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 20% ethyl acetate in petroleum ether) to give the compound of the present invention, methyl N-[[5-[2-(2,6-difluoro-4-nitrophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 118), as a solid (2 g). 1 H NMR (DMSO-d6): δ 8.77 (s, 1H), 8.45 (dd, J=9.2, 2 Hz, 2H), 7.80(s, 1H), 7.76-7.74(m, 1H), 7.69-7.66(m, 1H), 7.32(d, J=8.0Hz, 1H), 4.24(d, J=5.6 Hz, 2H), 3.55(s, 3H), 2.33(s, 3H). LCMS: m / z: 404 [M+H] + .
[0230] A solid was also obtained containing a mixture of N-[[5-[2-(2,6-difluoro-4-nitrophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate methyl (compound 118) and N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate methyl (compound 132). This solid was further purified by silica gel chromatography to obtain the compound of the present invention, N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-1,2,300-triazol-4-yl]-2-methylphenyl]methyl]carbamate methyl (compound 132) as a solid (800 mg). 1 H NMR (DMSO-d6): δ 9.08 (s, 1H), 8.50 (d, J=7.6 Hz, 2H), 7.83-7.82(m, 2H), 7.71-7.67(m, 2H), 7.29(d, 8.4Hz, 1H), 4.24(d, J=6.4Hz, 2H), 3.57(s, 3H), 2.32(s, 3H). LCMS: m / z:404[M+H] + .
[0231] Example 19 Preparation of methyl N-[[5-[2-(4-amino-2,6-difluorophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 115) To a mixture of methyl N-[[5-[2-(2,6-difluoro-4-nitrophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 18, Step F, compound 118) (2 g, 4.9 mmol) in ethanol (18 mL) and water (2 mL) was added iron powder (2.7 g, 49.6 mmol) and ammonium chloride (0.16 g, 2.9 mmol). The reaction mixture was heated to reflux for 1.5 h, stirred at room temperature for 16 h, then filtered through a pad of Celite® (diatomaceous earth filter aid) and rinsed with ethyl acetate (30 mL). The filtrate was diluted with water and extracted with ethyl acetate. The combined organics were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 30% ethyl acetate in petroleum ether) to give the title compound, a compound of the present invention, as a solid (1.6 g). 1 H NMR (CDCl3): δ 8.08(s, 1H), 7.74-7.73(m, 1H), 7.67-7.65(m, 1H), 7.24(s, 1H), 6.33-6.30( m, 2H), 4.89(br s, 1H), 4.42(d, J=5.2Hz, 2H), 4.13(s, 2H), 3.70(s, 3H), 2.37(s, 3H) LCMS: m / z:374[M+H] + .
[0232] The following compounds were prepared similarly to the method of Example 19: Methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 131). 1 H NMR(CDCl3):δ 7.91(s, 1H), 7.81(s, 1H), 7.70(d, 1H), 7.25(s, 1H), 6.35(d, 2H), 4.93(brs, 1H), 4.45(s, 2H), 4.19(brs, 2H), 3.71(s, 3H), 2.39(s, 3H).
[0233] Example 20 Preparation of methyl N-[[5-[2-(4-chloro-2,6-difluorophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (Compound 117) To a mixture of methyl N-[[5-[2-(4-amino-2,6-difluorophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (i.e., the product of Example 19) (1 g, 2.68 mmol) in carbon tetrachloride (125 mL) was added n-butyl nitrite (3.3 g, 32.17 mmol). The reaction mixture was heated to reflux for 16 hours and then filtered through a pad of Celite® (diatomaceous earth filter aid) and rinsed with ethyl acetate (20 mL). The filtrate was diluted with water (60 mL) and extracted with ethyl acetate. The combined organics were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluted with 30% ethyl acetate in petroleum ether) to give the title compound, a compound of the present invention, as a solid (0.12 g). 1 H NMR (CDCl3): δ 8.13(s, 1H), 7.74-7.73 (m, 1H), 7.66(dd, J=8.0, 1.6 Hz, 1H), 7.28(s, 1H), 7.19-7.15 (m, 2H), 4.90 (brs, 1H), 4.43(d, J=5.6 Hz, 2H), 4.71(s, 3H), 2.38(s, 3H). LCMS: m / z: 393 [M+H] + .
[0234] The following compounds were prepared similarly to the method of Example 20: Methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate (compound 121). 1 H NMR (CDCl3): δ 7.98(s, 1H), 7.79(brs, 1H), 7.70(d, J=6.4 Hz, 1H), 7.27-7.20(m, 3H), 4.91(br s, 1H), 4.44-4.43(m, 2H), 3.71(s, 3H), 2.38(s, 3H). LCMS: m / z: 393 [M+H] + .
[0235] The procedures described herein, together with methods known in the art, can be used to prepare the following compounds in Tables 1A-33D. The following abbreviations are used in the tables below: n means normal, i means iso, c means cyclo, Me means methyl, Et means ethyl, Pr means propyl, MeO means methoxy, EOt means ethoxy, MeS means methylthio, EtS means ethylthio, -CN means cyano, and -NO2 means nitro.
[0236] [Table 1]
[0237] This disclosure also includes Tables 2A through 33A, which respectively correspond to the column headings of Table 1A (i.e., "R 1 and R 2 The structure is the same as Table 1A above, except that the column headings "R is F" are replaced with the respective column headings shown below. For example, in Table 2A, the column headings are "R is F" and "R is F" are replaced with the respective column headings shown below. 1 and R 2 is Cl' and R 6 is as defined in Table 1A above.
[0238] [Table 2]
[0239] Table 1B Table 1B is the same as Table 1A except that the chemical structures in Table 1A are replaced with the following structures: [ka]
[0240] Tables 2B~33B Tables 2B-33B are constructed in a similar manner to Tables 2A-33A.
[0241] Table 1C Table 1C is the same as Table 1A except that the chemical structures in Table 1A are replaced with the following structures: [ka]
[0242] Tables 2C~33C Tables 2C-33C are constructed in a similar manner to Tables 2A-33A.
[0243] Table 1D Table 1D is the same as Table 1A except that the chemical structures in Table 1A are replaced with the following structures: [ka]
[0244] Tables 2D~33D Tables 2D-33D are constructed in a similar manner to Tables 2A-33A.
[0245] Formulation / Utility The compounds of formula 1 of the present invention (including their N-oxides, hydrates, and salts) are generally used as fungicidal active ingredients in compositions, i.e., formulations, together with at least one additional ingredient that functions as a carrier, selected from the group consisting of surfactants, solid diluents, and liquid diluents. The ingredients of the formulation or composition are selected to match the physical properties of the active ingredient, the mode of application, and environmental factors such as soil type, moisture, and temperature.
[0246] Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (emulsions, Examples of aqueous liquid compositions include liquid concentrates (including capsules), suspensions, emulsions (including microemulsions and / or suspoemulsions), which can optionally be thickened to form gels. Common types of aqueous liquid compositions are solutions, suspension concentrates (SC), capsule suspensions (CS), concentrated emulsions, microemulsions, and suspoemulsions. Common types of non-aqueous liquid compositions are emulsions, microemulsifiable concentrates, dispersible concentrates, and oil dispersions (OD).
[0247] Common types of solid compositions are dusts, powders, granules, pellets, pills, pastilles, tablets, filled films (including seed coatings), which may be water-dispersible ("wettable") or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. The active ingredient can be (micro)encapsulated and further formed into a suspension or solid dosage form; alternatively, the entire formulation of the active ingredient can be encapsulated (or "topcoated"). Encapsulation can control or delay the release of the active ingredient. Emulsifiable granules combine the advantages of both emulsion and dry granule formulations. High strength compositions are mainly used as intermediates for further formulation.
[0248] Sprayable formulations are typically spread in a suitable medium before spraying. Such liquid and solid formulations are formulated to be easily diluted with the spray medium, usually water, but which may be another suitable medium such as aromatic or paraffinic hydrocarbons or vegetable oils. Application rates may range from about 1 liter per hectare to several thousand liters, but more typically from about 10 liters per hectare to several hundred liters per hectare. Sprayable formulations may be tank-mixed with water or another suitable medium for foliar treatment by aerial or ground spraying, or for application to the plant's growing medium. Liquid and dry formulations may be metered directly into drip irrigation systems or into furrows during sowing. Liquid and solid formulations may be applied on the seeds of crops and desirable vegetation as seed treatments before sowing to protect emerging roots and other underground plant parts and / or leaves by systemic uptake.
[0249] The formulations typically contain effective amounts of active ingredient, diluent and surfactant within the following suitable ranges which total 100% by weight:
[0250] [Table 3]
[0251] Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and sodium bicarbonate, and sodium sulfate.Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Edition, Dorland Books, Caldwell, New Jersey.
[0252] Liquid diluents include, for example, water, N,N-dimethylalkanamides (e.g., N,N-dimethylformamide), limonene, dimethyl sulfoxide, N-alkylpyrrolidones (e.g., N-methylpyrrolidone), alkyl phosphates (e.g., triethyl phosphate), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oil, linear paraffin, isoparaffin), alkylbenzenes, alkylnaphthalenes, glycerin, glycerol triacetate, sorbitol, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone, and 4-hydroxy-4-methyl-2-pentane. Non-, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactates, dibasic esters, alkyl and aryl benzoates and gamma-butyrolactone, and alcohols which may be linear or branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents may also be used for saturated and unsaturated fatty acids (typically C6-C 22 glycerol esters of vegetable seed and fruit oils (e.g. olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grape seed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel oils), animal Liquid diluents also include fatty acids derived from plants (e.g., beef tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated), where the fatty acids can be obtained by hydrolysis of glycerol esters of vegetable and animal origin, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents guide, 2nd edition, Interscience, New York, 1950.
[0253] The solid and liquid compositions of the present invention often contain one or more surfactants. When added to a liquid, surfactants (also known as "surface active agents") generally modify, and most often reduce, the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in the surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifiers, or antifoaming agents.
[0254] Surfactants can be classified as nonionic, anionic or cationic.Nonionic surfactants useful in the compositions of the present invention include, but are not limited to:alkoxylated alcohols, such as those based on natural and synthetic alcohols (which may be branched or linear) and prepared from alcohols with ethylene oxide, propylene oxide, butylene oxide or mixtures thereof;ethoxylated amines, alkanolamides and ethoxylated alkanolamides;alkoxylated triglycerides, such as ethoxylated soybean oil, castor oil and rapeseed oil;alkylphenol alkoxylates, such as octylphenol ethoxylate, nonylphenol ethoxylate, dinonylphenol ethoxylate and dodecylphenol ethoxylate (prepared from phenol and ethylene oxide propylene oxide, butylene oxide or mixtures thereof);block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers in which the end blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty acid esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenols (including those made from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylated esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyl PEG (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycol (PEG); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.
[0255] Useful anionic surfactants include, but are not limited to: alkylarylsulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenylsulfonate derivatives; lignin and lignin derivatives, such as lignosulfonates; maleic or succinic acid or anhydrides; olefin sulfonates; phosphate esters, such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates, and phosphate esters of styrylphenol ethoxylates; protein-based surfactants; sarcosyl esters; Syn derivatives;styrylphenol ether sulfates;sulfates and sulfonates of oils and fatty acids;sulfates and sulfonates of ethoxylated alkylphenols;sulfates of alcohols;sulfates of ethoxylated alcohols;sulfonates of amines and amides, e.g., N,N-alkyl taurates;sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecyl benzene;sulfonates of condensed naphthalenes;sulfonates of naphthalene and alkyl naphthalenes;sulfonates of fractionated petroleum oils;sulfosuccinamidates; and sulfosuccinates and their derivatives. Examples of suitable sulfosuccinates include dialkyl sulfosuccinates.
[0256] Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as N-alkylpropanediamines, tripropylenetriamine, and dipropylenetetramine, as well as ethoxylated amines, ethoxylated diamines, and propoxylated amines (made from amines with ethylene oxide, propylene oxide, butylene oxide, or mixtures thereof); amine salts, such as amine acetate and diamine salts; quaternary ammonium salts, such as quaternary salts, ethoxylated quaternary salts, and diquaternary salts; and amine oxides, such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.
[0257] Mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants are also useful in the compositions of the present invention.Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in various published references, including McCutcheon's Emulsifiers and Detergents, Annual International and North American Editions, published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and AS Davidson and B. Milwidsky, Synthetic Detergents, 7th Edition, John Wiley and Sons, New York, 1987.
[0258] The compositions of the present disclosure may also contain formulation aids and additives known to those skilled in the art as formulation aids. Such formulation aids and additives may control: pH (buffering agents), foaming during processing (antifoaming agents such as polyorganosiloxanes (e.g., Rhodorsil® 416)), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), microbial growth in containers (antimicrobial agents), product freezing (antifreeze agents), color (dye / pigment dispersions (e.g., Pro-lzed® Colorant Red)), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetate, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymers, polyvinyl alcohol, polyvinyl alcohol copolymers, and waxes. Examples of formulation aids and additives include those listed in McCutcheon's Volume 2: Functional Materials, Annual International and North American Editions, published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT International Publication No. WO03 / 024222.
[0259] The compound of formula I and any other active ingredients are typically incorporated into the compositions of the present invention by dissolving the active ingredients in a solvent or by grinding in a liquid or dry diluent. Liquid formulations, including emulsions, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsion is water-immiscible, an emulsifier is typically added to emulsify the active ingredient-containing solvent upon dilution with water. Active ingredient slurries with particle sizes up to 2,000 μm can be wet-milled using a media mill to obtain particles with an average diameter of less than 3 μm. The aqueous slurry can be made into a finished SC formulation (see, for example, US 3,060,084) or can be further processed by spray drying to form water-dispersible granules. Dry formulations usually require a dry grinding process, which results in an average particle size in the range of 2-10 μm. Dusts and powders can be mixed and usually milled. They can be produced by grinding (e.g., using a hammer mill or a fluid energy mill). Granules and pellets can be produced by spraying the active substance onto a preformed granular carrier or by agglomeration techniques. See Browning, "Agglomeration", Chemical Engineering, December 4, 1967, pp. 147-48, Perry's Chemical Engineer's Handbook, 4th ed., McGraw-Hill, New York, 1963, pp. 8-57 and below, and WO 91 / 13546. Pellets can be produced as described in US 4,172,714. Water-dispersible and water-soluble granules can be produced as taught in US 4,144,050, US 3,920,442 and DE 3,246,493. Tablets can be produced as taught in US 5,180,587, US 5,232,701 and US 5,208,030. The films may be prepared as taught in GB 2,095,558 and US 3,299,566.
[0260] One embodiment of the present invention relates to a method for controlling fungal pathogens comprising diluting the fungal composition of the present invention (a compound of formula 1 formulated with a surfactant, a solid diluent and a liquid diluent, or a formulated mixture of a compound of formula 1 and at least one other fungicide) with water, and optionally adding an adjuvant to form a diluted composition, and contacting the fungal pathogen or its environment with an effective amount of the diluted composition.
[0261] Although a spray composition formed by diluting a sufficient concentration of the fungicidal composition of the present invention with water may provide sufficient efficacy to control fungal pathogens, a separately formulated adjuvant product may be added to the spray tank mix. These additional adjuvants are generally known as "spray adjuvants" or "tank mix adjuvants" and include any material mixed in the spray tank to improve the performance of the pesticide or to modify the physical properties of the spray mixture. Adjuvants may be anionic or nonionic surfactants, emulsifiers, petroleum-based crop oils, crop-derived seed oils, acidifiers, buffers, thickeners, or antifoaming agents. Adjuvants are used to enhance efficacy (e.g., bioavailability, adhesion, penetration, uniformity of coverage, and durability of protection), or to minimize or eliminate spray application problems related to incompatibility, foaming, drift, evaporation, volatilization, and decomposition. To obtain optimal performance, adjuvants are selected with respect to the properties of the active ingredient, the formulation, and the target (e.g., agricultural crops, pest insects).
[0262] The amount of adjuvant added to the spray mixture is generally in the range of about 2.5% to 0.1% by volume. The application rate of adjuvant added to the spray mixture is typically about 1 to 5 L per hectare. Representative examples of spray adjuvants include: Adigor® (Syngenta) 47% methylated rapeseed oil in liquid hydrocarbons, Silwet® (Helena Chemical Company) polyalkylene oxide modified heptamethyltrisiloxane, and Assist® (BASF) 17% surfactant blend in 83% paraffinic mineral oil.
[0263] One method of seed treatment is by spraying or dusting the seeds with the compound of the present invention (i.e., as a formulated composition) before sowing the seeds. The compositions formulated for seed treatment generally contain a film former or adhesive. Thus, typically, the seed coating composition of the present invention contains a biologically effective amount of a compound of formula 1 and a film former or adhesive. The seeds can be coated by spraying a flowable formulation directly onto a rotating bed of seeds and then drying the seeds. Alternatively, other formulations such as wettable powders, liquids, suspoemulsions, emulsions and emulsions in water can be sprayed onto the seeds. This process is particularly useful for forming a film on the seeds. A variety of coating machines and coating processes are available to those skilled in the art. Suitable processes include those described in P. Kosters et al., Seed Treatment: Progress and Prospects, 1999, 144:131-135, 19 ... 94 BCPC Mongraph No. 57, and those cited in the references cited therein.
[0264] For more information on formulation techniques, see Pesticide Chemistry and Bioscience, The Food-Environment Challenge, edited by T. Brooks and T. R. Roberts, Proceedings of the 9th International Congress on Pesticides and Chemical Substances. T. S. Woods, "The Formulator's Toolbox - Pesticide Chemistry," The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133 See "Product Forms for Modern Agriculture" in US 3,235,361, col. 6, line 16 to col. 7, line 19 and Examples 10-41; US 3,309,192, col. 5, line 43 to col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; US 2,891,855, col. 3, line 66 to col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1989. York, 1961, pp. 81-96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments See also in formulation technology, PJB Publications, Richmond, UK, 2000.
[0265] In the following examples, all percentages are by weight and all formulations are prepared by conventional methods. Compound numbers refer to compounds in Index Tables A-G. Without further elaboration, it is believed that one skilled in the art can use the preceding description to utilize the present invention to its full extent. Thus, the following examples are merely illustrative and should not be construed as limiting this disclosure in any way.
[0266] Example A high strength concentrate Compound 1 98.5% Silica aerosol 0.5% Synthetic amorphous fine silica 1.0%
[0267] Example B Wettable powder Compound 3 65.0% Dodecylphenol Polyethylene glycol ether 2.0% Sodium lignosulfonate 4.0% Sodium aluminosilicate 6.0% Montmorillonite (calcined) 23.0%
[0268] Example C Granules Compound 4 10.0% Attapulgite Granules (low volatility, 0.71 / 0.30 mm; USS No. 25-50 sieve) 90.0%
[0269] Example D Extrusion Molding Pellets Compound 5 25.0% Anhydrous sodium sulfate 10.0% Crude calcium lignosulfonate 5.0% Sodium alkylnaphthalene sulfonate 1.0% Calcium / Magnesium Bentonite 59.0%
[0270] Example E emulsion Compound 6 10.0% Polyoxyethylene sorbitol hexaoleate 20.0% C6-C 10 Fatty acid methyl ester 70.0%
[0271] Example F Microemulsion Compound 7 5.0% Polyvinylpyrrolidone-vinyl acetate copolymer 30.0% Alkyl polyglycoside 30.0% Glyceryl monooleate 15.0% Water 20.0%
[0272] Example G Seed treatment Compound 8 20.00% Polyvinylpyrrolidone-vinyl acetate copolymer 5.00% Montan Acid Wax 5.00% Calcium lignosulfonate 1.00% Polyoxyethylene / Polyoxypropylene Block Copolymer 1.00% Stearyl alcohol (POE20) 2.00% Polyorganosilane 0.20% Red pigment 0.05% Water 65.75%
[0273] Example H Fertilizer stick Compound 10 2.50% Pyrrolidone-styrene copolymer 4.80% Tristyrylphenyl 16-ethoxylate 2.30% Talc 0.80% Cornstarch 5.00% Sustained Release Fertilizer 36.00% Kaolin 38.00% Water 10.60%
[0274] Example I SC Agent Compound 33 35% Butyl polyoxyethylene / polypropylene block copolymer 4.0% Stearic acid / polyethylene glycol copolymer 1.0% Styrene acrylic polymer 1.0% Xanthan gum 0.1% Propylene glycol 5.0% Silicone defoamer 0.1% 1,2-Benzisothiazolin-3-one 0.1% Water 53.7%
[0275] Example J EW agent (Emulsion in Water) Compound 41 10.0% Butyl polyoxyethylene / polypropylene block copolymer 4.0% Stearic acid / polyethylene glycol copolymer 1.0% Styrene acrylic polymer 1.0% Xanthan gum 0.1% Propylene glycol 5.0% Silicone defoamer 0.1% 1,2-Benzisothiazolin-3-one 0.1% Aromatic petroleum hydrocarbons 20.0 Water 58.7%
[0276] Example K OD agent (Oil Dispersion) Compound 68 25% Hexaoleic acid Polyoxyethylene sorbitol 15% Organically modified bentonite clay 2.5% Fatty acid methyl ester 57.5%
[0277] Example L Suspo Emulsion Compound 115 10.0% Imidacloprid 5.0% Butyl polyoxyethylene / polypropylene block copolymer 4.0% Stearic acid / polyethylene glycol copolymer 1.0% Styrene acrylic polymer 1.0% Xanthan gum 0.1% Propylene glycol 5.0% Silicone defoamer 0.1% 1,2-Benzisothiazolin-3-one 0.1% Aromatic petroleum hydrocarbons 20.0% Water 53.7%
[0278] Water-soluble and wettable formulations are typically diluted with water to form an aqueous composition prior to application. Aqueous compositions for direct application to plants or parts thereof (e.g., spray tank compositions) typically contain at least about 1 ppm or more (e.g., 1 ppm to 100 ppm) of a compound of the invention.
[0279] Seeds are usually treated with an amount of about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed (i.e., about 0.0001 to 1% by weight of the seed before treatment). Flowable formulations formulated for seed treatment typically contain about 0.5 to about 70% active ingredient, about 0.5 to about 30% film-forming adhesive, about 0.5 to about 20% dispersant, 0 to about 5% thickener, 0 to about 5% pigments and / or dyes, 0 to about 2% defoamer, about 1% preservative, and volatile liquid. Contains 0 to approximately 75% diluent.
[0280] The compounds of the present invention are useful as plant disease control agents. Thus, the present invention further includes a method for controlling plant diseases caused by fungal plant pathogens, comprising applying an effective amount of the compounds of the present invention or a fungicidal composition containing the compounds to the plant or parts thereof to be controlled, or to the plant seeds to be controlled. The compounds and / or compositions of the present invention provide control of diseases caused by a wide range of fungal plant pathogens in the Ascomycota, Basidiomycota, Zygomycota, and fungal-like Oomycota. They are effective in controlling a wide range of plant diseases, especially foliar diseases, in ornamental plants, turf, vegetables, grounds, cereals, and fruit crops. These pathogens include, but are not limited to, those listed in Table 1-1. For Ascomycota and Basidiomycota, the names for both the sexual / sexual phase / metomorph as well as the asexual / metomorph (in brackets) are listed when known. Synonyms of pathogens are indicated by equal signs. For example, the sexual / anamorph / perfect age name Phaeosphaeria nodorum is followed by the corresponding asexual / anamorph / perfect age name Stagnospora nodorum and the synonymous archaic name Septoria nodorum.
[0281] [Table 4]
[0282] [Table 5]
[0283] In addition to their fungicidal activity, the compositions or combinations may also have antifungal activity against fire blight bacteria (Erwinia amylovora, Xanthomonas campestris, Pseudomonas syringae, and By controlling harmful microorganisms, the compounds of the present invention are useful for improving (i.e., increasing) the ratio of beneficial to harmful microorganisms in contact with crop plants or their propagules (e.g., seeds, corms, bulbs, tubers, cuttings) or in the agricultural environment of the crop plants or their propagules.
[0284] The compounds of the present invention are useful in the treatment of all plants, plant parts and seeds. Plant and seed varieties and cultivars can be obtained by conventional propagation and breeding methods or by genetic engineering methods. Genetically modified plants or seeds (transgenic plants or seeds) are those in which a heterologous gene (transgene) is stably integrated into the genome of the plant or seed. The transgene, defined by its specific location in the plant genome, is called a transformation or transgenic event.
[0285] Genetically modified plant varieties that can be treated according to the present invention include those that are resistant to one or more biotic stresses (pests such as nematodes, insects, mites, fungi, etc.) or abiotic stresses (drought, low temperature, soil salinity, etc.), or contain other desirable characteristics. Plants can be genetically modified to exhibit, for example, herbicide resistance, insect resistance, improved oil profile, or drought tolerance traits.
[0286] Treatment of genetically modified plants and seeds with the compounds of the invention may result in superadditive or enhanced effects, such as reduced application rates, broadened spectrum of activity, increased resistance to biotic and abiotic stresses or enhanced storage stability, which may be higher than would be expected from the mere additive effect of application of the compounds of the invention to genetically modified plants and seeds.
[0287] The compounds of the present invention are useful in seed treatments to protect the seeds from plant diseases. In the context of this disclosure and claims, treating the seeds means contacting the seeds with a biologically effective amount of the compounds of the present invention, which are typically formulated as compositions of the present invention. This seed treatment protects the seeds from soil-borne disease pathogens, and generally can also protect the roots and other plant parts in contact with the soil of the seedlings that develop from the germinating seeds. The seed treatment can also provide foliar protection by translocation of the compounds of the present invention or a second active ingredient within the developing plant. Seed treatments can be applied to all types of seeds, including those from which plants emerge that have been genetically transformed to express specialized traits. Representative examples include those that express proteins toxic to invertebrate pests, such as Bacillus thuringiensis toxins, or those that express herbicide resistance, such as glyphosate acetyltransferase, which confers resistance to glyphosate. Seed treatment with the compounds of the invention may also increase the vigour of the plant which grows from the seed.
[0288] The compounds of the present invention and their compositions, both alone and in combination with other fungicides, nematicides and insecticides, are particularly useful in seed treatments for agricultural crops, including, but not limited to, maize or corn, soybeans, cottonseed, cereals (e.g., wheat, oats, barley, rye and rice), potatoes, vegetables and rapeseed.
[0289] Additionally, the compounds of the present invention are useful in treating post-harvest diseases of fruits and vegetables caused by fungi and bacteria. These infections can occur before, during, and after harvest. For example, infections can occur before harvest and then remain dormant until some point during ripening (e.g., the host begins to change tissue in such a way that infection can progress); infections can also occur from superficial wounds caused by mechanical or insect damage. In this regard, the compounds of the present invention are useful in preventing losses due to post-harvest diseases that can occur at any time from harvest to consumption. The treatment of post-harvest diseases with the compounds of the present invention can increase the period during which perishable edible plant parts (e.g., fruits, seeds, leaves, stems, bulbs, tubers) can be stored refrigerated or unrefrigerated after harvest and remain edible and free of noticeable or harmful decomposition or contamination by fungi or other microorganisms. Treatment of edible plant parts before or after harvest with the compounds of the present invention can also reduce the formation of toxic metabolites of fungi or other microorganisms, such as mycotoxins, such as aflatoxins.
[0290] Plant disease control is usually achieved by applying an effective amount of the compounds of the present invention to the parts of the plants to be controlled, such as roots, stems, leaves, fruits, seeds, tubers or bulbs, before or after infection, or to the medium (soil or sand) in which the plants to be controlled grow. The compounds can also be applied to control seeds and seedlings that develop from the seeds. The compounds can also be applied through irrigation water to treat plants. Pre-harvest control of post-harvest pathogens that infect produce is typically achieved by field application of the compounds of the present invention, and if infection occurs after harvest, the compounds can be applied to the harvested crop as a dip, spray, fumigant, lining of treated packaging materials and boxes.
[0291] The application rate (i.e., fungicidally effective amount) for these compounds may be influenced by factors such as the plant disease to be controlled, the plant species to be controlled, ambient humidity and temperature, and should be determined under actual use conditions. Those skilled in the art can easily determine the fungicidally effective amount required for the desired level of plant disease control by simple experimentation. Foliage can usually be protected when treated with an amount of less than about 1 g / ha to about 5,000 g / ha of active ingredient. Seeds and seedlings can usually be protected when the seeds are treated with an amount of about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed.
[0292] The compounds of the present disclosure can also be mixed with one or more other biologically active compounds or agents to form multi-component pesticides that provide even broader agricultural protection, including fungicides, insecticides, nematicides, bactericides, acaricides, herbicides, herbicide safeners, growth regulators, such as insect molting inhibitors and rooting stimulants, chemo-sterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or insect pathogenic bacteria, viruses or fungi. Thus, the present disclosure also relates to a composition comprising a compound of formula I (in a fungicidally effective amount) and at least one additional biologically active compound or agent (in a biologically effective amount), which may further comprise at least one surfactant, solid diluent or liquid diluent. The other biologically active compound or agent can be formulated into a composition that comprises at least one surfactant, solid or liquid diluent. In the mixtures of the present disclosure, one or more other biologically active compounds or agents can be formulated together with the compound of formula I to form a premix, or one or more other biologically active compounds or agents can be formulated separately from the compound of formula I, and the formulations are mixed prior to application (e.g., in a spray tank) or, alternatively, applied sequentially.
[0293] As stated in the Summary of the Invention, one aspect of the invention is a fungicidal composition comprising (i.e., mixture or combination) a compound of formula 1, its N-oxide, or salt (i.e., component a), and at least one other fungicide (i.e., component b). Of note are combinations in which the other fungicidal active ingredient has a different site of action than the compound of formula 1. In certain instances, combinations with at least one other fungicidal active ingredient having a similar control spectrum but a different site of action are particularly advantageous for resistance management. Thus, the composition of the invention may further comprise a fungicidally effective amount of at least one additional fungicidal active ingredient having a similar control spectrum but a different site of action.
[0294] Of note, in addition to the compound of formula 1 as component (a), component (b) includes at least one fungicidal compound selected from the group consisting of FRAC-defined mechanism of action (MOA) classes: (A) nucleic acid synthesis, (B) mitosis and cell division, (C) respiration, (D) amino acid and protein synthesis, (E) signal transduction, (F) lipid synthesis and cell membrane integrity, (G) sterol biosynthesis in cell membranes, (H) cell wall biosynthesis in membranes, (I) melanin synthesis in cell walls, (P) host plant defense induction, multisite contact activity, and unknown mechanism of action.
[0295] The target sites of action recognized or proposed for FRAC along with their FRAC target site codes belonging to the above MOA classes are: (A1) RNA polymerase I, (A2) adenosine deaminase, (A3) DNA / RNP biosynthesis (proposed), (A4) DNA topoisomerase, (B1-B3) β-tubulin polymerization in mitosis, (B4) cell division (proposed), (B5) delocalization of spectrin-like proteins, (C1) complex I. NADH oxidoreductase, (C2) Complex II: succinate dehydrogenase, (C3) Complex III: cytochrome bc1 (ubiquinol oxidase) Qo site, (C4) Complex III: cytochrome bc1 (ubiquinone reductase) Qi site, (C5) uncoupling of oxidative phosphorylation, (C6) oxidative phosphorylation, inhibitor of ATP synthase, (C7) ATP production (proposed), (C8) Complex III: cytochrome bc1 (ubiquinone reductase) Qx (unknown) site, (D1) methionine biosynthesis (proposed), (D2-D5) protein biosynthesis, (E1) signal transduction (mechanism of action unknown), (E2-E3) histidine kinase in MAP / osmotic signal transduction, (F2 ) phospholipid biosynthesis, methyltransferases, (F3) lipid peroxidation (proposed), (F4) cell membrane permeability, fatty acids (proposed), (F6) microbial disruption of pathogen cell membranes, (F7) cell membrane disruption (proposed), (G1) C14-demethylase in sterol biosynthesis, (G2) Δ14-reductase and Δ8→Δ7-isomerase in sterol biosynthesis, (G3) 3-keto reductase, C4-demethylation, (G4) squalene epoxidase in sterol biosynthesis, (H3) trehalase and inositol biosynthesis, (H4) chitin synthase, (H5) cellulose synthase, (I1) reductase in melanin biosynthesis, and (I2) dehydratase in melanin biosynthesis.
[0296] Of particular note is the use of compounds of formula 1 as component (a) and, as component (b), of the classes (b1) benzimidazole methyl carbamate (MBC) fungicides; (b2) dicarboximide fungicides; (b3) demethylation inhibitor (DMI) fungicides; (b4) phenylamide fungicides; (b5) amine / morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor fungicides; (b8) hydroxy(2-amino-)pyrimidine fungicides; (b9) anilinopyrimidine fungicides; (b10) N-phenylcarbamic acid fungicides; (b11) quinone external inhibitor (QoI) fungicides; (b12) phenyl Lupyrrole fungicides; (b13) Azanaphthalene fungicides; (b14) Lipid peroxidation inhibitor fungicides; (b15) Melanin biosynthesis inhibitor-reductase (MBI-R) fungicides; (b16) Melanin biosynthesis inhibitor-dehydratase (MBI-D) fungicides; (b17) Sterol biosynthesis inhibitors (SBI): Class III fungicides; (b18) Squalene epoxidase inhibitor fungicides; (b19) Polyoxin fungicides; (b20) Phenylurea fungicides; (b21) Quinone internal inhibitor (QiI) fungicides; (b22) Benzamide and thiazole carboxamide fungicides; (b23) Enopyranuronic acid acid) antibiotic fungicides;(b24) hexopyranosyl antibiotic fungicides;(b25) glucopyranosyl antibiotic: protein synthesis fungicides;(b26) glucopyranosyl antibiotic: trehalase and inositol biosynthesis fungicides;(b27) cyanoacetamide oxime fungicides;(b28) carbamate fungicides;(b29) oxidative phosphorylation uncoupler fungicides;(b30) organotin fungicides;(b31) carboxylic acid fungicides;(b32) heteroaromatic fungicides;(b33) phosphonate fungicides;(b34) phthalamic acid fungicides;(b35) benzotriazine fungicides;(b36) benzene-sulfonamide fungicides;(b37) pyridazinone fungicides;(b38) thiophene-caproate fungicides ruboxamide fungicides; (b39) complex I NADH oxidoreductase inhibitor fungicides; (b40) carboxylic acid amide (CAA) fungicides; (b41) tetracycline antibiotic fungicides; (b42) thiocarbamate fungicides; (b43) benzamide fungicides; (b44) microbial fungicides; (b45) Q x(b46) plant extract fungicides; (b47) host plant defense induction fungicides; (b48) multisite contact active fungicides; (b49) fungicides other than those in classes (b1) to (b48); and at least one fungicidal compound selected from the group consisting of salts of compounds in classes (b1) to (b48).
[0297] Further description of these classes of fungicidal compounds is provided below.
[0298] (b1) "Benzimidazole methyl carbamate (MBC) fungicides" (FRAC code 1) inhibit mitosis by binding to β-tubulin during microtubule polymerization. Inhibition of microtubule polymerization can disrupt cell division, intracellular transport and cellular structure. Benzimidazole methyl carbamate fungicides include benzimidazole and thiophanate fungicides. Benzimidazoles include benomyl, carbendazim, fuberidazole and thiabendazole. Thiophanates include thiophanate and thiophanate-methyl.
[0299] (b2) "Dicarboximide fungicides" (FRAC code 2) inhibit MAP / histidine kinases in osmotic signaling. Examples include chlozolinate, iprodione, procymidone and vinclozolin.
[0300] (b3) "Demethylation inhibitor (DMI) fungicides" (FRAC code 3) (sterol biosynthesis inhibitors (SBI): class I) inhibit the C14-demethylase enzyme, which plays a role in sterol production. Sterols such as ergosterol are necessary for membrane structure and function and are essential for the development of a functional cell wall. Thus, exposure to these fungicides results in abnormal growth and even death of susceptible fungi. DMI fungicides are divided into several chemical classes: azoles (including triazoles and imidazoles), pyrimidines, piperazines, pyridines and triazolinethiones. Triazoles include azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, mefentrifluconazole, metconazole, myclobutanil, penconazole, propiconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, u Niconazol, Uniconazol-P, α-(1-chlorocyclopropyl)-α-[2-(2,2-dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1-ethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3 -(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, and rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1H-1,2,4-triazole.Imidazoles include econazole, imazalil, oxpoconazole, prochloraz, pefurazoate and triflumizole. Pyrimidines include fenarimol, nuarimol and triarimol. Piperazines include trifoli. The pyridines include buthiobate, pyrifenox, pyrisoxazole (3-[(3R)-5-(4-chlorophenyl)-2,3-dimethyl-3-isoxazolidinyl]pyridine, a mixture of 3R,5R- and 3R,5S-isomers) and (αS)-[3-(4-chloro-2-fluorophenyl)5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol. The triazolinethiones include prothioconazole and 2-[2-(1-chlorocyclopropyl)-4-(2,2-dichlorocyclopropyl)2-hydroxybutyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione. Biochemical studies have shown that all of the above fungicides are DMI fungicides as described by KH Kuck et al. in Modern Selective Fungicides-Properties, Applications and Mechanisms of Action, H. Lyr (ed.), Gustav Fischer Verlag: New York, 1995, 205-258.
[0301] (b4) "Phenylamide fungicides" (FRAC code 4) are specific inhibitors of RNA polymerase in oomycete fungi. Susceptible fungi exposed to these fungicides show a reduced ability to incorporate uridine into rRNA. Growth and development in susceptible fungi is prevented by exposure to this class of fungicides. Phenylamide fungicides include acylalanine, oxazolidinone and butyrolactone fungicides. The acylalanines include benalaxyl, benalaxyl-M (also known as kiralaxyl), furalaxyl, metalaxyl and metalaxyl-M (also known as mefenoxam). The oxazolidinones include oxadixyl. The butyrolactones include ofurace.
[0302] (b5) “Amine / morpholine fungicides” (FRAC code 5) (SBI: class II) target two sites in the sterol biosynthetic pathway, Δ 8 →Δ 7 Isomerase and Δ 14 They inhibit reductases. Sterols such as ergosterol are necessary for membrane structure and function and are essential for the development of functional cell walls. Thus, exposure to these fungicides results in abnormal growth and even death of susceptible fungi. Amine / morpholine fungicides (also known as non-DMI sterol biosynthesis inhibitors) include morpholine, piperidine and spiroketal-amine fungicides. Morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. Piperidines include fenpropidin and piperalin. Spiroketal-amines include spiroxamine.
[0303] (b6) "Phospholipid biosynthesis inhibitor fungicides" (FRAC code 6) inhibit fungal growth by affecting phospholipid biosynthesis. Phospholipid biosynthesis fungicides include the phosphorothiolate and dithiolane fungicides. The phosphorothiolates include edifenphos, iprobenphos and pyrazophos. The dithiolanes include isoprothiolane.
[0304] (b7) "Succinate dehydrogenase inhibitor (SDHI) fungicides" (FRAC code 7) inhibit complex II fungal respiration by disrupting a key enzyme in the Krebs cycle (TCA cycle) called succinate dehydrogenase. Inhibition of respiration prevents fungi from making ATP and therefore inhibits growth and reproduction. SDHI fungicides include phenylbenzamides, furancarboxamides, oxathiinecarboxamides, thiazolecarboxamides, pyrazole-4-carboxamides, pyridinecarboxamides, phenyloxoethyl Thiophenamides and pyridinylethylbenzamides. Benzamides include benodanil, flutolanil and mepronil. Furancarboxamides include fenfuram. Oxathiincarboxamides include carboxin and oxycarboxin. Thiazolecarboxamides include thifluzamide.Pyrazole-4-carboxamides include benzovindiflupyr (N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide), bixafen, fluindapyr, fluxapyroxad (3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)-1H-pyrazole-4-carboxamide), furametpyr, isoflucipram, and isopyrazam. (3-(difluoromethyl)-1-methyl-N-[1,2,3,4-tetrahydro-9-(1-methylethyl)-1,4-methanonaphthalen-5-yl]-1H-pyrazole-4-carboxamide), Penflufen (N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide), Penthiopyrad, Pydiflumetofen, Sedaxane (N-[2-[1,1'-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide), N-[2-(1S,2R)-[1,1'-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, 3-(difluoromethyl)-N-(2,3-dihydro-1,1,3-trimethyl-1H-indene- 4-yl)-1-methyl-1H-pyrazole-4-carboxamide, N-[2-(2,4-dichlorophenyl)2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[[2-(1-methylethyl)phenyl]methyl]-1H-pyrazole-4-carboxamide. Pyridinecarboxamides include boscalid. Phenyloxoethylthiophenamides include isofetamide (N-[1,1-dimethyl-2-[2-methyl-4-(1-methylethoxy)phenyl]-2-oxoethyl]-3-methyl-2-thiophenecarboxamide).The pyridinylethylbenzamides include fluopyram.
[0305] (b8) "Hydroxy-(2-amino-)pyrimidine fungicides" (FRAC code 8) inhibit nucleic acid synthesis by interfering with adenosine deaminase. Examples include bupirimate, dimethirimol and ethirimol.
[0306] (b9) "Anilidopyrimidine fungicides" (FRAC code 9) are proposed to inhibit the biosynthesis of the amino acid methionine and disrupt the secretion of hydrolytic enzymes that lyse plant cells during infection. Examples include cyprodinil, mepanipyrim and pyrimethanil.
[0307] (b10) "N-phenylcarbamic acid fungicides" (FRAC code 10) bind to β-tubulin and inhibit mitosis by disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, intracellular transport and cellular structure. Examples include diethofencarb.
[0308] (b11) "Quinone external inhibitor (QoI) fungicides" (FRAC code 11) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinol oxidase. The oxidation of ubiquinol is mediated by the "quinone external" (QoI) enzyme of the cytochrome bc1 complex located in the inner mitochondrial membrane of fungi. o ) site. Inhibition of mitochondrial respiration interferes with normal fungal growth and development. Quinone external inhibitor fungicides include: These include methoxyacrylates, methoxycarbamates, oxyiminoacetates, oxyiminoacetamides and dihydrodioxazine fungicides (collectively known as strobilurin fungicides), as well as oxazolidinedione, imidazolinone and benzylcarbamate fungicides. Methoxyacrylates include azoxystrobin, coumoxystrobin, ((αE)-2-[[(3-butyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]-α-(methoxymethylene)methyl benzeneacetate), enoxastrobin ((αE)-2-[[[(E)-[(2E)-3-(4-chlorophenyl)-1-methyl-2-propen-1-ylidene]amino]oxy]methyl]-α-(methoxymethylene)methyl benzeneacetate) (also known as enestroburin), flufenoxystrobin ((αE)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-α-(methoxymethylene)methyl benzeneacetate), picoxystrobin, and pyraoxystrobin. ((αE)-2-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]oxy]methyl]-α-(methoxymethylene)benzene methyl acetate). Methoxycarbamates include pyraclostrobin, pyrametostrobin (N-[2-[[(1,4-dimethyl-3-phenyl-1H-pyrazol-5-yl)oxy]methyl]phenyl]-N-methoxycarbamate methyl) and triclopyricarb (N-methoxy-N-[2-[[(3,5,6-trichloro-2-pyridinyl)oxy]methyl]phenyl]carbamate methyl). Oxyiminoacetates include kresoxim-methyl and trifloxystrobin.Examples of oxyiminoacetamides include dimoxystrobin, fenaminstrobin ((αE)-2-[[[(E)-[(2E)-3-(2,6-dichlorophenyl)-1-methyl-2-propen-1-ylidene]amino]oxy]methyl]-α-(methoxyimino)-N-methylbenzeneacetamide), metominostrobin, orysastrobin, and α-[methoxyimino]-N-methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]methyl]benzeneacetamide. Examples of dihydrodioxazines include fluoxastrobin. Examples of oxazolidinediones include famoxadone. Examples of imidazolinones include fenamidone. Examples of benzylcarbamates include pyribencarb. Class (b11) also includes mandestrobin (2-[(2,5-dimethylphenoxy)methyl]-α-methoxy-N-benzeneacetamide).
[0309] (b12) "Phenylpyrrole fungicides" (FRAC code 12) inhibit MAP / histidine kinases involved in osmotic signaling in fungi. Fenpiclonil and fludioxonil are examples of this fungicide class.
[0310] (b13) "Azanaphthalene fungicides" (FRAC code 13) are proposed to inhibit signal transduction by an as yet unknown mechanism. They have been shown to interfere with germination and / or appressorium formation in powdery mildew causing fungi. Azanaphthalene fungicides include aryloxyquinolines and quinazolinones. Aryloxyquinolines include quinoxyfen. Quinazolinones include proquinazid.
[0311] (b14) "Lipid peroxidation inhibitor fungicides" (FRAC code 14) are proposed to inhibit lipid peroxidation, which affects membrane synthesis in fungi. Members of this class, such as etridiazole, may also affect other biological processes, such as respiration and melanin biosynthesis. Lipid peroxidation fungicides include aromatic hydrocarbons and 1,2,4-thiadiazole fungicides are included. Aromatic hydrocarbon fungicides include biphenyl, chloroneb, dicloran, quintozene, tecnazene and tolclofos-methyl. 1,2,4-thiadiazoles include etridiazole.
[0312] (b15) "Melanin biosynthesis inhibitor-reductase (MBI-R) fungicides" (FRAC code 16.1) inhibit the naphthal reduction step in melanin biosynthesis. Melanin is necessary for host plant infection by some fungi. Melanin biosynthesis inhibitor-reductase fungicides include isobenzofuranone, pyrroloquinolinone and triazolobenzothiazole fungicides. Isobenzofuranones include fthalide. Pyrroloquiolinones include pyroquilon. Triazolobenzothiazoles include tricyclazole.
[0313] (b16) "Melanin biosynthesis inhibitor-dehydratase (MBI-D) fungicides" (FRAC code 16.2) inhibit scytalone dehydratase in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitor-dehydratase fungicides include cyclopropanecarboxamide, carboxamide and propionamide fungicides. Cyclopropanecarboxamides include carpropamid. Carboxamides include diclocymet. Propionamides include fenoxanil.
[0314] (b17) "Sterol biosynthesis inhibitors (SBI): Class III fungicides (FRAC code 17) inhibit 3-ketoreductase during C4-demethylation in sterol production. SBI: Class III inhibitors include hydroxyanilide and amino-pyrazolinone fungicides. Hydroxyanilides include fenhexamid. Amino-pyrazolinones include fenpyrazamine (S-2-propen-1-yl 5-amino-2,3-dihydro-2-(1-methylethyl)-4-(2-methylphenyl)-3-oxo-1H-pyrazole-1-carbothioate).
[0315] (b18) "Squalene epoxidase inhibitor fungicides" (FRAC code 18) (SBI: Class IV) inhibit squalene epoxidase in the sterol biosynthetic pathway. Sterols such as ergosterol are necessary for membrane structure and function and are essential for the development of functional cell walls. Thus, exposure to these fungicides results in abnormal growth and even death of susceptible fungi. Squalene epoxidase inhibitor fungicides include thiocarbamate and allylamine fungicides. Thiocarbamates include pyributicarb. Allylamines include naftifine and terbinafine.
[0316] (b19) "Polyoxin fungicides" (FRAC code 19) are inhibitors of chitin synthase. Examples include polyoxins.
[0317] (b20) "Phenylurea fungicides" (FRAC code 20) are proposed to affect cell division. An example is pencycuron.
[0318] (b21) "Quinone internal inhibitor (QiI) fungicides" (FRAC code 21) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase. The reduction of ubiquinone is via the "quinone internal" (QiI) enzyme of the cytochrome bc1 complex. i) site, which is located in the fungal inner mitochondrial membrane. By inhibiting mitochondrial respiration, normal fungal growth and development is disrupted. Quinone internal inhibitor fungicides include cyanoimidazole and sulfamoyltriazole fungicides. Cyanoimidazoles include cyazofamid. Sulfamoyltriazoles and An example is amisulbrom.
[0319] (b22) "Benzamide and thiazolecarboxamide fungicides" (FRAC code 22) inhibit mitosis by binding to β-tubulin and disrupting microtubule polymerization. Inhibition of microtubule polymerization can disrupt cell division, intracellular transport and cellular structure. Benzamides include zoxamide. Thiazolecarboxamides include ethaboxam.
[0320] (b23) “Enopyranuronic acid antibiotic fungicides” (FRAC code 23) inhibit fungal growth by affecting protein biosynthesis. An example is blasticidin-S.
[0321] (b24) "Hexopyranosyl antibiotic fungicides" (FRAC code 24) inhibit fungal growth by affecting protein biosynthesis. An example is kasugamycin.
[0322] (b25) “Glucopyranosyl antibiotics: protein synthesis fungicides” (FRAC code 25) inhibit fungal growth by affecting protein biosynthesis. An example is streptomycin.
[0323] (b26) "Glucopyranosyl antibiotics: trehalase and inositol biosynthesis fungicides" (FRAC code 26) inhibit trehalase and inositol biosynthesis. An example is validamycin.
[0324] (b27) "Cyanoacetamide oxime fungicides (FRAC code 27) include cymoxanil.
[0325] (b28) "Carbamate fungicides" (FRAC code 28) are considered multisite inhibitors of fungal growth. They are proposed to interfere with fatty acid synthesis in the cell membrane and subsequently disrupt nuclear permeability. Propamacarb, iodocarb, and prothiocarb are examples of this fungicide class.
[0326] (b29) "Oxidative phosphorylation uncoupler fungicides" (FRAC code 29) inhibit fungal respiration by uncoupling oxidative phosphorylation. Inhibition of respiration prevents normal fungal growth and development. This class includes 2,6-dinitroanilines such as fluazinam and dinitrophenyl crotonates such as dinocap, meptyldinocap and binapacryl.
[0327] (b30) "Organotin fungicides" (FRAC code 30) inhibit adenosine triphosphate (ATP) synthase in the oxidative phosphorylation pathway. Examples include fentin acetate, fentin chloride and fentin hydroxide.
[0328] (b31) "Carboxylic acid fungicides" (FRAC code 31) inhibit fungal growth by affecting deoxyribonucleic acid (DNA) topoisomerase type II (gyrase). An example is oxolinic acid.
[0329] (b32) "Heteroaromatic fungicides" (Fungicide Resistance Action Committee (FRAC) code 32 Heteroaromatic fungicides include the isoxazoles and isothiazolones. The isoxazoles include hymexazole and the isothiazolones include octhilinone.
[0330] (b33) "Phosphonate fungicides" (FRAC code 33) include phosphorous acid and its various salts, including fosetyl aluminium.
[0331] (b34) "Phthalamic acid fungicides" (FRAC code 34) include teclofthalam.
[0332] (b35) "Benzotriazine fungicides" (FRAC code 35) include triazoxide.
[0333] (b36) "Benzene-sulfonamide fungicides" (FRAC code 36) include flusulfamide.
[0334] (b37) “Pyridazinone fungicides” (FRAC code 37) include diclomedine.
[0335] (b38) "Thiophene-carboxamide fungicides" (FRAC code 38) have been proposed to affect ATP production. An example is silthiofam.
[0336] (b39) "Complex I NADH oxidoreductase inhibitor fungicides" (FRAC code 39) inhibit electron transport in mitochondria and include pyrimidinamines such as diflumetrim, and pyrazole-5-carboxamides such as tolfenpyrad.
[0337] (b40) "Carboxylic acid amide (CAA) fungicides" (FRAC code 40) inhibit cellulose synthase, which impedes growth and leads to death of the target fungus. Carboxylic acid amide fungicides include cinnamamide, valinamide and other carbamate and mandelamide fungicides. Cinnamamides include dimethomorph, flumorph and pyrimorph (3-(2-chloro-4-pyridinyl)-3-[4-(1,1-dimethylethyl)phenyl]-1-(4-morpholinyl)-2-propen-1-one). Valinamides and other carbamates include benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, tolprocarb (2,2,2-trifluoroethyl N-[(1S)-2-methyl-1-[[(4-methylbenzoyl)amino]methyl]propyl]carbamate) and valifenalate (methyl N-[(1-methylethoxy)carbonyl]-L-valyl-3-(4-chlorophenyl)-β-alaninate) (also known as valiphenal). Mandelic acid amides include mandipropamide, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide, and N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide.
[0338] (b41) "Tetracycline antibiotic fungicides" (FRAC code 41) inhibit fungal growth by affecting protein synthesis. Examples are oxytetracycline, Examples include phosphorus.
[0339] (b42) "Thiocarbamic acid fungicides" (FRAC code 42) include metasulfocarb.
[0340] (b43) "Benzamide fungicides" (FRAC code 43) inhibit fungal growth by delocalization of spectrin-like proteins. Examples include the pyridinylmethylbenzamide fungicides (now FRAC code 7, pyridinylethylbenzamides), such as fluopicolide.
[0341] (b44) "Microbicide agents" (FRAC code 44) disrupt fungal pathogen cell membranes. Microbicide agents include Bacillus species such as Bacillus amyloliquefaciens strains QST 713, FZB24, MB1600, D747 and the bactericidal lipopeptides they produce.
[0342] (b45) Q x I fungicide" (FRAC code 45) is an unknown (Q x Q) site inhibits complex III mitochondrial respiration in fungi by affecting ubiquinone reductase. Inhibition of mitochondrial respiration interferes with normal growth and development of fungi. x I Fungicides include triazolopyrimidylamines such as amethoctrazine (5-ethyl-6-octyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine).
[0343] (b46) "Plant extract fungicides" are proposed to act by disrupting cell membranes. Plant extract fungicides include terpene hydrocarbons and terpene alcohols, such as extracts from Melaleuca alternifolia (tea tree).
[0344] (b47) "Host plant defense induction fungicides" (FRAC code P) induce the defense mechanisms of the host plant. Host plant defense induction fungicides include the benzothiadiazoles, benzisothiazoles and thiadiazole-carboxamide fungicides. The benzothiadiazoles include acibenzolar-S-methyl. The benzisothiazoles include probenazole. The thiadiazole-carboxamides include thiadinil and isotianil.
[0345] (b48) “Multiple-site contact-active fungicides” inhibit fungal growth through multiple sites of action and have contact / preventive action. This class of fungicides includes: (b48.1) "copper fungicides" (FRAC code M1), (b48.2) "sulfur fungicides" (FRAC code M2), (b48.3) "dithiocarbamate fungicides" (FRAC code M3), (b48.4) "phthalimide fungicides" (FRAC code M4), (b48.5) "chloronitrile fungicides" (FRAC code M5), (b48.6) "sulfamide fungicides" (FRAC code M6), (b48.7) multisite contact "guanidine fungicides" (FRAC code M7), (b48.8) "triazine fungicides" (FRAC code M8), (b48.9) "quinone fungicides" (FRAC code M9), (b48.10) "quinoxaline fungicides" (FRAC code M10) and (b48.11) "maleimide fungicides" (FRAC code M11). "Copper fungicides" are inorganic compounds that contain copper, typically in the copper(II) oxidation state; examples include copper oxychloride, copper sulfate, and copper hydroxide, including compositions such as Bordeaux mixture (tribasic copper sulfate). "Sulfur fungicides" are inorganic chemicals that contain a ring or chain of sulfur atoms; examples include elemental sulfur. "Dithiocarbamate fungicides" contain a dithiocarbamate molecular moiety; examples include mancozeb, metiram, propineb, ferbam, maneb, thiram, zineb, and ziram. "Phthalic "Imide fungicides" contain a phthalimide molecular moiety; examples include folpet, captan, and captafol. "Chloronitrile fungicides" contain aromatic rings substituted with chloro and cyano; examples include chlorothalonil. "Sulfamide fungicides" include dichlofluanid and tolyfluanid. Multisite contact "guanidine fungicides" include guazatine, iminoctadine albesilate, and iminoctadine triacetate. "Triazine fungicides" include anilazine. "Quinone fungicides" include dithianone. "Quinoxaline fungicides" include quinomethionate (also known as chinomethionate). "Maleimide fungicides" include fluoroimide.
[0346] (b49) "Fungicides other than those of classes (b1) to (b48)" includes certain fungicides whose mode of action is unknown. These include: (b49.1) "phenyl-acetamide fungicides" (FRAC code U6), (b49.2) "aryl-phenyl-ketone fungicides" (FRAC code U8), (b49.3) "guanidine fungicides" (FRAC code U12), (b49.4) "thiazolidine fungicides" (FRAC code U13), (b49.5) "pyrimidine-hydrazone fungicides" (FRAC code U14) and (b49.6) compounds that bind to oxysterol-binding proteins as described in PCT International Publication WO2013 / 009971. Phenyl-acetamides include cyflufenamid and N-[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]-methylene]benzeneacetamide. Aryl-phenyl ketones include benzophenones such as metraphenone, and benzoylpyridines such as pyriophenone (5-chloro-2-methoxy-4-methyl-3-pyridinyl)(2,3,4-trimethoxy-6-methylphenyl)methanone). Quanidines include dodine. Thiazolidines include fluthianil ((2Z)-2-[[2-fluoro-5-(trifluoromethyl)phenyl]thio]-2-[3-(2-methoxyphenyl)-2-thiazolidinylidene]acetonitrile). Pyrimidinone hydrazones include ferimzone. The (b49.6) class is oxathiapiproline. (1-[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone) and its R-enantiomer which is 1-[4-[4-[5R-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Registry Number 1003319-79-6).(b49) class includes bethoxazin, flometoquin carbonate (2-ethyl-3,7-dimethyl-6-[4-(trifluoromethoxy)phenoxy]-4-quinolinyl methyl), fluorimide, neo-asozin (iron methanearsonate), picarbutrazox (1,1-dimethylethyl N-[6-[[[[((Z)1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate), pyrrolnitrin, quinomethionate, tebufloquine (6-(1,1-dimethylethyl)-8-fluoro-2,3-dimethyl-4-quinolinyl acetate), and tolnifanide. (N-(4-chloro-2-nitrophenyl)-N-ethyl-4-methylbenzenesulfonamide), 2-butoxy-6-iodo-3-propyl-4H-1-benzopyran-4-one, 3-butyn-1-yl, N-[6-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, (N-(4-chloro-2-nitrophenyl)-N-ethyl-4-methylbenzenesulfonamide), N'-[4-[4-chloro-3-(trifluoromethyl. )phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, N-[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]benzeneacetamide, 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone, 5-fluoro-2-[(4-methylphenyl)methoxy]-4-pyrimidinamine, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine and N-[1-[[[1-(4-cyano
[0033] The (b46) class also includes 4-fluorophenyl N-[6-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, pentyl N-[4-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-thiazolyl]carbamate and pentyl N-[6-[[[[(Z)-(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate. In addition to the specific classes above (e.g., (b1), (b10) and (b22)), the (b46) class further includes mitotic inhibitors and cytostatic fungicides.
[0347] Further "fungicides other than those in classes (1) to (46)" whose mechanism of action is unknown or has not yet been classified include fungicidal compounds selected from the components (b49.7) to (b49.12) shown below.
[0348] Component (b49.7) is given by formula 49.7 [ka] [In the formula, R b1 teeth [ka] The present invention relates to a compound in which:
[0349] Examples of compounds of formula b49.7 include (b49.7a) (2-chloro-6-fluorophenyl)methyl 2-[1-[2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate (Registry No. 1299409-40-7) and (b49.7b) (1R)-1,2,3,4-tetrahydro-1-naphthalenyl 2-[1-[2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate (Registry No. 1299409-42-9). Methods for preparing compounds of formula b46.2 are described in PCT International Publication Nos. WO2009 / 132785 and WO2011 / 0 This is described in No. 51243.
[0350] Component (b49.8) is the formula b49.8 [ka] [In the formula, R b2 is CH3, CF3 or CHF2; R b3 is CH3, CF3 or CHF2; R b4 is halogen or cyano; and n is 0, 1, 2 or 3.
[0351] Examples of compounds of formula b49.8 include (b49.8a) 1-[4-[4-[5-[(2,6-difluorophenoxy)methyl]-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone. Methods for preparing compounds of formula b49.8 are described in PCT International Patent Application No. PCT / US11 / 64324.
[0352] The component (b4799) is the formula b49.9 [ka] [In the formula, R b5is -CH2OC(O)CH(CH3)2, -C(O)CH3, -CH2OC(O)CH3, -C(O)OCH2CH(CH3)2 or [ka] The present invention relates to a compound in which:
[0353] Examples of compounds of formula b49.9 include: (b49.9a) 2-methylpropanoate [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl (Registry No. 517875-34-2); (b49.9b) 2-methylpropanoate (3S,6S,7R,8R)-3-[[[3-(acetyloxy)-4-methoxy-2-pyridinyl]carbamoyl] (b49.9c) 2-Methylpropanoic acid (3S,6S,7R,8R)-3[[[3[(acetyloxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl (Registry number 517875-31-9), (b49.9d) 2-Methylpropanoic acid (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(2-methylpropoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl (Registry No. 328256-72-0), and (b49.9e) N-[[3-(1,3-benzodioxol-5-ylmethoxy)-4-methoxy-2-pyridinyl]carbonyl]-O-[2,5-dideoxy-3-O-(2-methyl-1-oxopropyl)-2-(phenylmethyl)L-arabinonoyl]-L-serine, (1→4')-lactone (Registry No. 1285706-70-8). Methods for preparing compounds of formula b49.9 are described in PCT Publication Nos. WO99 / 40081, WO2001 / 014339, WO2003 / 035617 and WO2011044213.
[0354] Component (b49.10) is given by formula 49.10 [ka] [In the formula, R b6 is H or F, and R b7 is -CF2CHFCF3 or -CF2CF2H. Examples of compounds of formula b49.10 include (b49.10a) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide (Registry No. 1172611-40-3) and (b49.10b) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide (Registry No. 923953-98-4). Compounds of formula 49.10 can be prepared by the methods described in PCT International Publication WO2007 / 017450.
[0355] Component b49.11 is the formula b49.11 [ka] [In the formula, R b8 is halogen, C1-C4 alkoxy or C2-C4 alkynyl; R b9 is H, halogen or C1-C4 alkyl; R b10 is C1-C 12 Alkyl, C1-C 12 Haloalkyl, C1-C 12 Arco Kishi, C2-C 12 Alkoxyalkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C4-C 12 Alkoxyalkenyl, C4-C 12 Alkoxyalkynyl, C1-C 12 Alkylthio or C2-C 12 is alkylthioalkyl; R b11 is methyl or -Y b13 -R b12 and; R b12 is C1-C2 alkyl; and Y b13 is CH2, O or S. The present invention relates to a compound of the formula:
[0356] Examples of compounds of formula b49.11 include: (b49.11a) 2-[(3-bromo-6-quinolinyl)oxy]-N-(1,1-dimethyl-2-butyn-1-yl)-2-(methylthio)acetamide, (b49.11b) 2[(3-ethynyl-6-quinolinyl)oxy]-N-[1-(hydroxymethyl)-1-methyl-2-propyn-1-yl]-2-(methylthio)acetamide, (b49.11c) N-(1,1-dimethyl-2-butyn-1-yl)-2-[(3-ethynyl-6-quinolinyl)oxy]-2-(methylthio)acetamide, (b49.11d) 2-[(3-bromo-8-methyl-6-quinolinyl)oxy]-N-(1,1-dimethyl-2-propyn-1-yl)-2-(methylthio)acetamide and (b49.11e) 2-[(3-bromo-6-quinolinyl)oxy]-N-(1,1-dimethylethyl)butanamide. Compounds of formula b49.11, their use as fungicides and methods for their preparation are generally known; see, for example, PCT International Publications WO2004 / 047538, WO2004 / 108663, WO2006 / 058699, WO2006 / 058700, WO2008 / 110355, WO2009 / 030469, WO2009 / 049716 and WO2009 / 087098.
[0357] Component 49.12 relates to N'-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, which is believed to inhibit C24-methyltransferase involved in the biosynthesis of sterols.
[0358] Of note, therefore, are mixtures (i.e., compositions) comprising a compound of formula 1 and at least one germicidal compound selected from the group consisting of classes (1)-(49) above. Also of note are compositions comprising the above mixtures (in germicidal effective amounts) and further comprising at least one additional component selected from the group consisting of surfactants, solid diluents, and liquid diluents. Of particular note are mixtures (i.e., compositions) comprising a compound of formula 1 and at least one germicidal compound selected from the group of specific compounds listed above relating to classes (1)-(49). Also of particular note are compositions comprising the above mixtures (in germicidal effective amounts) and further comprising at least one additional surfactant selected from the group consisting of surfactants, solid diluents, and liquid diluents.
[0359] Examples of component (b) fungicides include acibenzolar-S-methyl, aldimorph, amethoctrazine, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl (including benalaxyl-M), benodanil, benomyl, benthiavalicarb (including benthiavalicarb-isopropyl), benzovindiflupyr, bethoxadin, binapacryl, biphenyl, bitertanol, bixafen, blasticidin-S, boscalid, bromuconazole, bupirimate, and bupirimate. Thiobate, Captafol, Captan, Carbendazim, Carboxin, Carpropamid, Chloroneb, Chlorothalonil, Chlozolinate, Clotrimazole, Copper hydroxide, Copper oxychloride, Copper sulfate, Cumoxystrobin, Cyazofamid, Cyflufenamid, Cymoxanil, Cyproconazole, Cyprodinil, Dichlofluanid, Diclocymet, Diclomedine, Dicloran, Diethofencarb, Difenoconazole, Diflumetrim, Dimethirimol, Dimethomorph, Dimoxystrobin , diniconazole (including diniconazole-M), dinocap, dithianone, dithiolanes, dodemorph, dodine, econazole, edifenphos, enoxastrobin (also known as enestrobin), epoxiconazole, etaconazole, ethaboxam, ethirimol, etridiazole, famoxadone, fenamidone, fenarimol, phenaminestrobin, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin a acetate, fentin chloride, fentin hydroxide, ferbam, ferimzone, flometoquin, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluindapyr, flumorph, fluopicolide, fluopyram, flouroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, fthalide, fuberidazole, furalaki Sil, furametpyr, guazatine, hexaconazole, hymexazole, imazalil, imibenconazole, iminoctadine albesilate, iminoctadine triacetate, iodocarb, ipconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isofetamide, isoprothiolane, isoflucipram, isopyrazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandepropamid, mandestrobin, maneb, mepanipyrim, mepronil, meptyldinocap, Metalaxyl (including metalaxyl-M / mefenoxam), mefentrifluconazole, metconazole, methasulfocarb, metiram, metominostrobin, metrafenone, miconazole, myclobutanil, naftifine, neo-azocine, nuarimol, octhilinone, ofurace, orysastrobin, oxadixyl, oxathiapiproline, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, pefurazoate, penconazole, pencycuron, penflufen, penthiopyrad, phosphorous acid (salts thereof, e.g.(including fosetyl-aluminum), picarbutrazox, picoxystrobin, piperalin, polyoxin, probenazole, prochloraz, procymidone, propamacarb, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pyraclostrobin, pyrametostrobin, pyroxystrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriophenone, pyrisoxazole, pyroquilon, pyrrolnitrin, quinconazole, quinomethionate, quinoxyfen, quintozene, sedaxane, silthiofam, simeconazole, spiroxamine ... Treptomycin, sulfur, tebuconazole, tebufloquine, tecloftalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolnifanide, tolprocarb, trifluanid, riadimefon, triadimenol, triarimol, triticonazole, triazoxide, tribasic copper sulfate, tricyclazole, triclopyricarb, tridemorph, trifloxystrobin, triflumizole, triforine, trimorphamide, uniconazole, uniconazole-P, validamycin, valifenalate (also known as valifenal), vinclozolin, zineb, ziram, zoxamide, 2-methylpropanoic acid (3S,6S,7R,8R)-3-[[[3-[(acetyloxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl, 2-methylpropanoic acid (3S,6S,7R,8R)-3-[[[3-(acetyloxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 4-Methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl, N-[[3-(1,3-benzodioxol-5-ylmethoxy)-4-methoxy-2-pyridinyl]carbonyl]-O-[2,5-dideoxy-3-O-(2-methyl-1-oxopropyl)-2-(phenylmethyl)-L-arabinonoyl]-L-serine, (1→4')-lactone,N-[2-(1S,2R)-[1,1'-bicyclopropyl]-2-ylphenyl]-3-, (Difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, 2-[(3-bromo-6-quinolinyl)oxy]-N-(1,1-dimethyl-2-butyn-1-yl)-2-(methylthio)acetamide, 2-[(3-bromo-6-quinolinyl)oxy]-N-(1,1-dimethylethyl)butanamide, 2-[(3-bromo-8-methyl-6-quinolinyl)oxy]-N-(1,1-dimethyl-2-propyn-1-yl)-2-(methylthio)acetamide, 2-butoxy-6-iodo-3-propyl-4H-1-benzopyran -4-one, N-[6-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate 3-butyn-1-yl, α-(1-chlorocyclopropyl)-α-[2-(2,2-dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1-ethanol, 2-[2-(1-chlorocyclopropyl)-4-(2,2-dichlorocyclopropyl)-2-hydroxybutyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, (αS)-[3-(4 -chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, rel-1-[[(2R,3S) -3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1H-1,2,4-triazole, 3-[5-(4-chlorophenyl)-2,3-dimethyl-3-isoxazolidinyl]pyridine, 2-[1-[2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate (2-chloro-6-fluorophenyl)methyl, N'-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-Thiadiazol-5-yl]oxy]-2,5-dimethylphenyl]-N-ethyl-N-methyl-methanimidamide, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide , N'-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[[2-(1-methylethyl)phenyl]methyl]-1H-pyrazole-4-carboxamide, N-[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]benzeneacetamide, N-[2-(2,4-dichloro phenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, N-(3',4'-difluoro[1,1'-biphenyl]-2-yl)-3-(trifluoromethyl)-2-pyrazinecarboxamide, 3-(difluoromethyl)-N-(2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide, 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2, 3,3,3-Hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide, 5,8-difluoro-N-[2-[3-methoxy-4-[[4-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]ethyl]-4-quinazolinamine, 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, 1-[4-[4-[5R-[(2,6-difluorophenoxy)methyl]-4,5-Dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, N-(1,1-dimethyl-2-butyne-1-, yl)-2-[(3-ethynyl-6-quinolinyl)oxy]-2-(methylthio)acetamide, 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone, 2-[(3-ethynyl-6-quinolinyl)oxy]-N-[1-(hydroxymethyl)-1-methyl-2-propyn-1-yl]-2-(methylthio)acetamide, N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbamic acid 4-fluorophenyl, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine, 5-fluoro-2-[(4-methylphenyl)methoxy]-4-pyrimidinamine, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(2-methylpropoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl-2-methylpropanoate, α-(methoxyimino)-N-methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]methyl]benzeneacetamide, 2-methylpropanoate [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl, pentyl N-[6-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, pentyl N-[4-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-thiazolyl]carbamate, and pentyl N-[6-[[[[(Z)-(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate and (1R)-1,2,3,4-tetrahydro-1-naphthalenyl 2-[1-[2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate. Of note therefore are fungicidal compositions comprising as component (a) a compound of formula 1 (or an N-oxide or salt thereof) and as component (b) at least one fungicide selected from the preceding list.
[0360] Of particular note are combinations of a compound of formula 1 (or an N-oxide or salt thereof) (i.e., component (a) in the composition) with azoxystrobin, benzovindiflupyr, bixafen, captan, carpropamid, chlorothalonil, copper hydroxide, copper oxychloride, copper sulfate, cymoxanil, cyproconazole, cyprodinil, diethofencarb, difenoconazole, dimethomorph, epoxiconazole, ethaboxam, fenarimol, fenhexamid, fluazinam, fludioxonil, fluindapyr, fluopyram, flusilazole, flutianil, lutriafol, fluoxamer ... Sapiroxad, folpet, iprodione, isofetamide, isoflucipram, isopyrazam, kresoxim-methyl, mancozeb, mandestrobin, meptyldinocap, metalaxyl (including metalaxyl-M / mefenoxam), mefentrifluconazole, metconazole, metrafenone, myclobutanil, oxathiapiproline, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g., fosetyl-aluminium), picoxystrobin, propiconazole, proquinazid, prothioconazole, pyraclostrobin, pyrimethanil, sedaxane Spiroxamine, sulfur, tebuconazole, thiophanate-methyl, trifloxystrobin, zoxamide, α-(1-chlorocyclopropyl)-α-[2-(2,2-dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1-ethanol, 2-[2-(1-chlorocyclopropyl)-4-(2,2-dichlorocyclopropyl)-2-hydroxybutyl]-1,2-dihydro-3 H-1,2,4-triazole-3-thione, N-[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, 3-(difluoromethyl)-N-(2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide, 1-[4-[4- [5R-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, N-[6-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate 1,1-dimethylethyl, 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine, 5-fluoro-2-[(4-methylphenyl)methoxy]-4-pyrimidinamine, (αS)-[3 -(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, and rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1H-1,2,4-triazole. (i.e., as component (b) in the composition).
[0361] Examples of other biologically active compounds or agents that may be formulated with the compounds of the present invention are: Invertebrate pest control compounds or agents, such as abamectin, acephate, acetamiprid, acrinathrin, aphidopyropene (cyclopropanecarboxylic acid [(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-6,12-dihydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-2H,11H-naphtho[2,1-b]pyrano[3,4-e]pyran-4-yl]methyl), amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, buprofezin, carbofuran, cartap, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyantraniliprole (3-bromo-1-(3-chloro-2-pyridinyl)-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1H-pyrazole-5-carboxamide), cyclaniliprole (3-bromo-N-[2-bromo-4-chloro-6-[[(1-cyclopropylethyl)amino]carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide), cycloxaprid ((5S,8R)-1-[(6-chloro-3-pyridinyl)methyl]-2,3,5,6,7,8-hexahydro-9-nitro-5,8-epoxy-1H-imidazo[1,2-a]azepine), cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, flufenoxystrobin ((αE)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-α-(methoxymethylene)benzeneacetate methyl), fluensulfone (5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)sulfonyl]thiazole), flupiprole (1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[(2-methyl-2-propene, -1-yl)amino]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile), flupyradifurone (4-[[(6-chloro-3-pyridinyl)methyl](2,2-difluoroethyl)amino]-2(5H)-furanone), tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos, halofenozide, heptafluthrin (2,2-dimethyl-3-[(1Z)-3,3,3-trifluoro-1-propen-1-yl]cyclopropanecarboxylate [2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl), hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, meperfluthrin ((1R,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate [2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl), metaflumizone, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, methoxyfenozide, metofluthrin, milbemycin oxime, momfluorothrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl-3-(2-cyano-1-propen-1-yl)-2,2-dimethylcyclopropanecarboxylate), monocrotophos, nicotine, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, piflubumid (1,3,5-trimethyl-N-(2-methyl-1-oxopropyl)-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-1H-pyrazole-4-carboxamide), parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrins, pyridalyl, pyrifluquinazon, pyriminostrobin ((αE)-2-[[[2-[(2,4-dichlorophenyl)amino]-6-(trifluoromethyl)-4-pyrimidinyl]oxy]methyl]-α-(methoxymethylene)benzeneacetate methyl), pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulfoxaflor, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tolfenpyrad, tralomethrin, triazamate, trichlorfon and triflumuron; and biological agents including entomopathogenic bacteria, such as Bacillus thuringiensis subsp. aizawai, Bacillus thuringiensis subsp. kurstaki, and encapsulated delta-endotoxins of Bacillus thuringiensis (e.g., Cellcap, MPV, MPVII); entomopathogenic fungi, such as green muscardine fungus); and insect pathogenic viruses, including nuclear polyhedrosis viruses (NPVs) such as baculovirus, HzNPV, and AfNPV; and granulosis viruses (GVs) such as CpGV.
[0362] The compounds and compositions of the invention may be applied to plants that have been genetically transformed to express a protein toxic to invertebrate pests (e.g., Bacillus thuringiensis delta-endotoxin). The effect of the exogenously applied fungicidal compounds of the invention may be provided as an enhanced effect with the expressed toxin protein.
[0363] General references for agricultural protection agents (i.e. insecticides, fungicides, nematicides, acaricides, herbicides and biologicals) include The Pesticide Manual, 13th Edition, CDS Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, UK, 2003 and The BioPesticide Manual, 2nd Edition, L. g. Copping, Ed., British Crop Protection Council, Farnham, Surrey, UK, 2001.
[0364] For embodiments in which one or more of these various mixing partners are used, the weight ratio of these various mixing partners (total) to the compound of formula 1 is typically between about 1:3000 and about 3000:1. Of note is a weight ratio between about 1:300 and about 300:1 (e.g., between about 1:30 and about 30:1). Those skilled in the art can easily determine the biologically effective amount of active ingredient required for the desired range of biological activity by simple experimentation. It will be clear that the inclusion of these additional ingredients can expand the range of diseases controlled beyond that controlled by the compound of formula 1 alone.
[0365] In certain instances, the combination of the compounds of the present invention with other biologically active (especially fungicidal) compounds or agents (i.e., active ingredients) may produce greater-than-additive (i.e., enhanced) effects. It is always desirable to reduce the amount of active ingredient released into the environment while ensuring effective pest control. If the enhanced effect of the fungicidal active ingredient occurs at an application rate that produces an agronomically satisfactory level of fungal control, such a combination may be advantageous for reducing crop production costs and reducing environmental load.
[0366] Also, in certain instances, the combination of the compounds of the present invention with other biologically active compounds or agents may produce less-than-additive (i.e., safening) effects on beneficial organisms in the agricultural environment. For example, the compounds of the present invention may safen herbicides on crop plants or protect beneficial insect species (e.g., insect predators, pollinators such as honeybees) from pesticides.
[0367] Fungicides of note for formulation with the compounds of formula 1 to provide mixtures useful in seed treatment include, but are not limited to, amisulbrom, azoxystrobin, boscalid, carbendazim, carboxin, cymoxanil, cyproconazole, difenoconazole, dimethomorph, florylpicoxamide, fluazinam, fludioxonil, flufenoxystrobin, fluquinconazole, fluopicolide, fluoxastrobin, flutriafol, These include fluxapyroxad, ipconazole, iprodione, metalaxyl, mefenoxam, mefentrifluconazole, metconazole, myclobutanil, paclobutrazole, penflufen, picoxystrobin, prothioconazole, pyraclostrobin, sedaxane, silthiofam, tebuconazole, thiabendazole, thiophanate-methyl, thiram, trifloxystrobin and triticonazole.
[0368] Invertebrate pest control compounds or agents that can be formulated with the compounds of Formula 1 to provide useful mixtures in seed treatments include, but are not limited to, abamectin, acetamiprid, acrinathrin, afidopiropen, amitraz, avermectin, azadirachtin, bensultap, bifenthrin, buprofezin, cadusafos, carbaryl, carbofuran, cartap, chlorantraniliprole, chlorfenapyr, chlorpyrifos, clothianidin, cyantraniliprole, cyclaniliprole, cyflutrix, cyclohexyl ether ... beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, dieldrin, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, etofenprox, etoxazole, fenothiocarb, fenoxycarb, fenvalerate, fipronil, flonicamid, flubendiamide, fluensulfone, flufenoxuron, flufiprole, flupyradifurone, fluvalinate, formetanate, hosthiazate, heptafluthrin, hexaflumuron, hydramethylnon, isofenvalerate, Midacloprid, indoxacarb, lufenuron, meperfluthrin, metaflumizone, methiocarb, methomyl, methoprene, methoxyfenozide, momfluorothrin, nitenpyram, nithiazine, novaluron, oxamyl, piflubumid, pymetrozine, pyrethrins, pyridaben, pyriminostrobin, pyridalyl, pyriproxyfen, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulfoxaflor, tebufenozide, tetramethrin, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, triflumuron, Bacillus thuringiensis delta-endotoxin, Bacillus thuringiensis virus strains and Nucleo polyhydrosis virus strains.
[0369] Compositions containing the compounds of formula 1 useful for seed treatment may further include bacteria and fungi having the ability to provide protection from the harmful effects of plant pathogenic fungi or bacteria and / or soil-born animals such as nematodes. Bacteria exhibiting nematicidal properties may include, but are not limited to, Bacillus firmus, Bacillus cereus, Bacillus subtiliis, and Pasteuria penetrans. A suitable Bacillus firmus strain is CNCM I-1582 strain (GB-126), which is available from BioNem. TM It is commercially available as NCMM I-1592. A suitable Bacillus cereus strain is the NCMM I-1592 strain. Both Bacillus strains are disclosed in US 6,406,690. Other suitable bacteria exhibiting nematicidal activity are B. amyloliquefaciens IN937a and B. subtilis strain gB03. Bacteria exhibiting bactericidal properties may include, but are not limited to, B. pumilus strain gB34. Fungal species exhibiting nematicidal properties may include, but are not limited to, Myrothecium verrucaria, Paecilomyces lilacinus, and Purpureocillium lilacinum.
[0370] The seed treatment may also include one or more nematicides of natural origin, such as elicitor proteins called harpins, which are isolated from certain bacterial plant pathogens, such as fire blight (Erwinia amylovora). One example is N-Hibit TM and Harpin-N-Tek seed treatment technology available as Gold CST.
[0371] The seed treatment may also include one or more species of legume rhizobia, such as the microsymbiotic nitrogen fixing bacterium Bradyrhizobium japonicum. These inocculants may optionally include one or more lipo-chitooligosaccharides (LCOs), which are nodulation (Nod) factors produced by rhizobia during the initiation of nodule formation on the roots of legume plants. For example, the Optimize® seed treatment technology uses the LCO Promoter in combination with an inocula. Technology TM Incorporate.
[0372] The seed treatment may also include one or more isoflavones that can increase the level of root colonization by mycorrhizal fungi. Mycorrhizal fungi improve plant growth by enhancing root uptake of nutrients such as water, sulfate, nitrate, phosphate, and metals. Examples of isoflavones include, but are not limited to, genistein, biochanin A, formononetin, daidzein, glycitein, hesperetin, naringeni, and pratensein. Formononetin is available as an active ingredient in mycorrhizal inoculant products such as PHC Colonize® AG.
[0373] The seed treatment may also include one or more plant activators that induce systemic acquired resistance in the plant after contact with the pathogen. An example of a plant activator that induces such a protection mechanism is acibenzolar-S-methyl.
[0374] The following tests demonstrate the control efficacy of the compounds of the invention against certain pathogens. However, the pathogen control protection provided by the compounds is not limited to these species. See Index Tables A-E below for compound descriptions. The following abbreviations are used in Index Tables A-E: Me means methyl, i-Pr means isopropyl, c-Pr means cyclopropyl, i-Bu means isobutyl, c-Bu means cyclobutyl, t-Bu means tert-butyl, and NO2 means nitro. The abbreviation "Cmpd." stands for "Compound" and the abbreviation "Ex." stands for "Example" and is followed by a number indicating the compound prepared in that example. The abbreviation "mp" stands for melting point. "AP" stands for "melting point." + The value reported in the "(M+1)" column is the H to the molecule with the highest isotopic abundance (i.e., M). + (molecular weight 1) is the molecular weight of the observed molecular ion formed by the addition of one or more higher atomic mass isotopes of lower abundance (e.g., 37 Cl, 81 The presence of molecular ions containing Br is not reported. The reported MS peaks were observed by mass spectrometry using electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI).
[0375] [Table 6]
[0376] [Table 7]
[0377] [Table 8]
[0378] [Table 9]
[0379] [Table 10]
[0380] [Table 11]
[0381] [Table 12]
[0382] [Table 13]
[0383] [Table 14]
[0384] Biological Examples of the Invention General protocol for preparing test suspensions for Tests A-F: Test compounds were first dissolved in acetone in an amount equal to 3% of the final volume, then suspended at the desired concentration (ppm) in acetone and purified water (50 / 50 (by volume) mixture) containing 250 ppm of the surfactant PEG400 (polyhydric alcohol ester). The resulting suspensions were then used in Tests A-F.
[0385] Test A The test solutions were sprayed at the run-off point on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of Zymoseptoria tritici (cause of wheat leaf blight) and incubated at 24°C in a saturated atmosphere for 48 h, then transferred to a growth chamber at 20°C for 17 days, after which period disease scoring was performed.
[0386] Test B The test solution was sprayed at the runoff point on wheat seedlings. The following day, the seedlings were tritici (cause of wheat leaf rust) and incubated at 20°C in a saturated atmosphere for 24 hours, then transferred to a growth room at 20°C for 7 days, after which period disease scoring was carried out.
[0387] Test C The test suspensions were sprayed at the runoff point onto wheat seedlings. The following day the seedlings were inoculated with a spore dust of Blumeria graminis f.sp. tritici (also known as Erysiphe graminis f.sp. tritici, the causal agent of wheat powdery mildew) and incubated in a growth room at 20°C for 8 days, after which period a visual disease score was made.
[0388] Test D The test solutions were sprayed at the runoff point of soybean seedlings. The following day the seedlings were inoculated with a spore suspension of Phakopsora pachyrhizi (cause of Asian soybean rust) and incubated at 22°C in a saturated atmosphere for 24 hours, then transferred to a growth room at 22°C for 8 days, after which period visual disease scores were made.
[0389] Test E The test suspensions were sprayed at the runoff point onto tomato seedlings. The following day the seedlings were inoculated with a spore suspension of Botrytis cinerea (the causal agent of tomato grey mould) and incubated at 20°C in a saturated atmosphere for 48 hours, then transferred to a growth room at 24°C for 3 days, after which time visual disease scores were made.
[0390] Test F The test suspensions were sprayed at the runoff point onto the tomato seedlings. The following day the seedlings were inoculated with a spore suspension of Alternaria solani (cause of early blight of tomato) and incubated at 27°C in a saturated atmosphere for 48 hours, then transferred to a growth room at 20°C for 3 days, after which period visual disease scores were made.
[0391] The results for Tests A through F are shown in Table A below. A score of 100 indicates 100% disease control and a score of 0 indicates no disease control (compared to the control). A dash (-) indicates that the compound Indicates not tested.
[0392] [Table 15]
[0393] [Table 16]
[0394] [Table 17]
[0395] [Table 18]
[0396] [Table 19]
Claims
1. Formula 1 [Formula 1] [In the formula, A is, [chemical 2] is a radical selected from the group consisting of wherein the bond extending to the right is attached to the ring containing Q and the bond extending to the left is Y-N(R 3 ) C(=W)R 4 attached to a substituted phenyl ring; Q is CR 6 or N; Y is CR 7a R 7b , O or NR 8 and W is O or S; R 1 and R 2 are each independently halogen, cyano, hydroxy, nitro, amino, 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Haloalkenyl, C 2 -C 6 Alkynyl, C 2 -C 6 Haloalkynyl, C 2 -C 6 Cyanoalkyl, C 3 -C 6 Cycloalkyl, C 3 -C 6 Halocycloalkyl, C 4 -C 8 Cycloalkylalkyl, C 2 -C 6 Alkoxyalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 2 -C 6 Alkenyloxy, C 2-C 6 Haloalkenyloxy, C 2 -C 6 Alkynyloxy, C 2 -C 6 Haloalkynyloxy, C 2 -C 6 Cyanoalkoxy, C 3 -C 6 Cycloalkoxy, C 4 -C 8 Cycloalkylalkoxy, C 2 -C 6 Alkoxyalkoxy, C 1 -C 6 Alkylthio, C 1 -C 6 Haloalkylthio, C 1 -C 6 Alkylsulfinyl, C 1 -C 6 Haloalkylsulfinyl, C 1 -C 6 Alkylsulfonyl or C 1 -C 6 haloalkylsulfonyl; R 3 is H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyclopropyl, C 2 -C 4 Alkylcarbonyl, C 2 -C 4 Haloalkylcarbonyl, C 2 -C 4 Alkoxycarbonyl or C 2 -C 4 haloalkoxycarbonyl; R 4 is C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 1 -C 3 Alkoxy, C 1 -C 3 Haloalkoxy, C 1 -C 3 Alkylamino or C 2-C 4 is dialkylamino; Each R 5 are independently halogen, cyano, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 1 -C 3 Alkoxy or C 1 -C 3 haloalkoxy; n is 0, 1 or 2; R 6 is H, halogen, cyano, hydroxy, nitro, amino, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Haloalkenyl, C 2 -C 6 Alkynyl, C 2 -C 6 Haloalkynyl, C 2 -C 6 Cyanoalkyl, C 1 -C 6 Hide Roxyalkyl, C 2 -C 6 Alkoxyalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 2 -C 6 Alkenyloxy, C 2 -C 6 Haloalkenyloxy, C 2 -C 6 Alkynyloxy, C 2 -C 6 Haloalkynyloxy, C 2 -C 6 Cyanoalkoxy, C 2 -C 6 Alkoxyalkoxy, C 1 -C 6 Alkylamino, C 1 -C 6 Alkylthio, C 1 -C 6 Haloalkylthio, C 1 -C 6 Alkylsulfinyl, C 1 -C 6 Haloalkylsulfinyl, C 1 -C 6 Alkylsulfonyl, C 1 -C 6 Haloalkylsulfonyl, -ZC(=O)V, CR 10a = NOR 10b , ON=CR 11a R 11b , C.R. 12a = NNR 12b R 12c or -L-J; R 7a is H, hydroxy, halogen, cyano, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 2 -C 3 Alkoxyalkyl, C 1 -C 3 Alkoxy, C 1 -C 3 Haloalkoxy, C 1 -C 3 Alkylsulfinyl or C 1 -C 3 alkylsulfonyl; R 7b is H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 2 -C 3 Alkoxyalkyl, C 1 -C 3 Alkoxy or C 1 -C 3 haloalkoxy; R 8 is H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 2 -C 3 Alkylcarbonyl or C 2 -C 3 haloalkylcarbonyl; Z is a direct bond, O, S, or NH; or CH optionally substituted with up to two substituents independently selected from halogen, methyl, or methoxy. 2 and V is R 9 OR 9 and R 9 , R 10b , R 11a and R 12c are H and C, respectively. 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Haloalkenyl, C 2 -C 4 Alkynyl, C 3 -C 6 Cycloalkyl, C 3 -C 6 Halocycloalkyl or C 4 -C 8 cycloalkylalkyl; R 10a , R 11b , R 12a and R 12b are each independently H, C 1 -C 3 Alkyl or C 1 -C 3 haloalkyl; L is a direct bond, CH 2 ,O.S.,N.R. 13 , O.C.H. 2 , C.H. 2 O, C(=O), S(=O) or S(=O) 2 and J is a 3- to 6-membered non-aromatic carbocyclic ring, where up to 3 carbon atom ring members are independently selected from C(=O) and C(=S), and each ring is selected from R 14 optionally substituted with up to four substituents independently selected from J is a 3-6 membered heterocyclic ring, each ring containing ring members selected from carbon atoms and 1-4 heteroatoms independently selected from up to 2 O atoms, up to 2 S atoms, and up to 4 N atoms, where up to 3 carbon atom ring members are independently selected from C(=O) and C(=S), and each ring is selected from R 14 optionally substituted with up to four substituents independently selected from: R 13 is H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 2 -C 3 Alkylcarbonyl or C 2 -C 3 haloalkylcarbonyl; Each R 14 are independently halogen, hydroxy, cyano, nitro, C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Haloalkenyl, C 1 -C 4 Alkoxy, C 1 -C 4 Haloalkoxy or C(=O)OR 15 and Each R 15 are independently H, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Haloalkenyl, C 2 -C 4 Alkynyl, C 3 -C 6 Cycloalkyl or C 3 -C 6 halocycloalkyl], its tautomers, N-oxides, and salts.
2. During the ceremony: A is A-1, A-3 or A-4; Q is CR 6 and Y is CR 7a CR 7b and W is O; R 1 and R 2 Each independently represents a halogen, C 1 -C 3 Alkyl, C 1 -C 3 HelloA Rukill, C 2 -C 4 Alkoxyalkyl, C 1 -C 3 Alkoxy, C 1 -C 3 Haloalkoxy, C 2 -C 4 Alkenyloxy, C 2 -C 4 Haloalkenyloxy, C 2 -C 4 Alkoxyalkoxy or C 1 -C 3 is alkylthio; R 3 is H, methyl, methylcarbonyl or methoxycarbonyl; R 4 is methyl, methoxy, ethoxy, methylamino or dimethylamino; Each R 5 is independently halogen or methyl; R 6 is H, halogen, nitro, amino, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Haloalkenyl, C 2 -C 6 Alkynyl, C 2 -C 6Haloalkynyl, C 2 -C 6 Alkoxyalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 2 -C 6 Alkenyloxy, C 2 -C 6 Haloalkenyloxy, C 2 -C 6 Alkynyloxy, C 2 -C 6 Haloalkynyloxy, C 2 -C 6 Alkoxyalkoxy, C 1 -C 6 Alkylthio, C 1 -C 6 Haloalkylthio, -ZC(=O)V, CR 10a = NOR 10b , C.R. 12a = NNR 12b R 12c or -L-J; R 7a is H, halogen, methyl or methoxy; R 7b is H or methyl; Z is a direct bond, O, NH, CH 2 or CH(OCH 3 ) and R 9 , R 10b and R 12c are H and C, respectively. 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 2 -C 4 Alkenyl or C 2 -C 4 haloalkenyl; R 10a , R 12a and R 12b are each independently H, methyl or halomethyl; L is a direct bond, CH 2 , O, OCH 2or CH 2 O; J is J-1 to J-71 [C3] [C4] [C5] [C6] is selected from wherein the floating bond is connected to L through any available carbon or nitrogen atom of the depicted ring; and x is 0, 1, 2, or 3; Each R 14 are independently halogen, methyl, methoxy or C(═O)OR 15 and Each R 15 is independent, C 1 -C 3 Alkyl, C 1 -C 3 The compound of claim 1 which is haloalkyl or cyclopropyl.
3. During the ceremony: A is A-1; R 1 and R 2 are each independently Br, Cl, F, methyl, trifluoromethyl, methoxy, or trifluoromethoxy; R 3 is H or methyl; R 4 is methyl, methoxy or ethoxy; Each R 5 is methyl; R 6 is H, halogen, amino, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, C 1 -C 3 Alkoxy, C 1 -C 3 Haloalkoxy, C 2 -C 4 Alkenyloxy, C 2 -C 4 Haloalkenyloxy, CR 10a = NOR 10b or -L-J; R 7a is H or methyl; R 7b is H or methyl; R 10b is H, methyl, C 2 -C 4 Alkenyl or C 2 -C 4 haloalkenyl; R 10a is H or methyl; L is a direct bond, O or OCH 2 and J is J-6, J-22, J-35, J-37, J-58, J-64, J-65, J-66, J-67, J-69, or J-70; and Each R 14 is independently halogen or methyl; The compound according to claim 2.
4. During the ceremony: R 1 and R 2 are each independently Cl, F or methyl; R 3 is H; R 4 is methoxy; n is 0; R 6 is H, Br, Cl, I, amino, methyl, i-propyl, trifluoromethyl, CH 2 F, C.H.F. 2 , methoxy, ethoxy, i-propyloxy, trifluoromethoxy, CH 2 F.O., C.F. 2 O, CH=NOCH 3 , CH=NOCH 2 CH 3 , C(CH 3 ) = NOCH 3 or -L-J; R 7a is H; R 7b is H; and J is J-65, J-66 or J-67; The compound according to claim 3.
5. During the ceremony: R 1 and R 2 are each independently Cl or F; R 6 is H, Br, Cl, I, amino, methoxy, ethoxy, i-propyloxy, trifluoromethoxy, CHF 2 O, C(CH 3 ) = NOCH 3 or -L-J; J is J-66 or J-67; x is 0, 1 or 2; and R 14 is Br, Cl, F or methyl; The compound according to claim 4.
6. During the ceremony: R 1 and R 2 are F, respectively; R 6 is H, Br, Cl, amino, methoxy, ethoxy or i-propyloxy; The compound according to claim 5.
7. Methyl N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(2,6-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methyl-phenyl]methyl]carbamate; Methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(4-bromo-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(2,6-difluoro-4-iodophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(2,6-difluoro-4-hydroxyphenyl)-1H-pyrazol-3-yl]-2-methyl-phenyl]methyl]carbamate; Methyl N-[[5-[1-(4-ethoxy-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methyl-phenyl]methyl]carbamate; Methyl N-[[5-[1-[4-(cyclobutyloxy)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethoxy)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[4-(difluoromethoxy)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[2,6-difluoro-4-(2-propyn-1-yloxy)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(2,6-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(4-cyclopropyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methyl-phenyl]methyl]carbamate; N-[[5-[1-[4-[(1,1-dimethylethyl)thio]-2,6-difluoro phenyl-1H-pyrazol-3-yl-2-methylphenyl]methyl]carbamic acid methyl ester; Methyl N-[[5-[1-[4-[(difluoromethyl)thio]-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(4-ethynyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(2,6-dichloro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[4-(cyclopropyloxy)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(2,6-difluoro-4-formylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(4-acetyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; 3,5-difluoro-4-[3-[3-[[(methoxycarbonyl)amino]methyl]-4-methyl-phenyl]-1H-pyrazol-1-yl]benzoate methyl; Methyl N-[[5-[1-[2,6-difluoro-4-(hydroxymethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[2,6-difluoro-4-[1-(methoxyimino)ethyl]phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-[4-(difluoromethyl)-2,6-difluorophenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[2-[2,6-difluoro-4-(1-methylethyl)phenyl]-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[2-(4-amino-2,6-difluorophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[2-(4-chloro-2,6-difluorophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[2-(2,6-difluoro-4-nitrophenyl)-2H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate; Methyl N-[[5-[1-(4-amino-2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate; and Methyl N-[[5-[1-(2,6-difluoro-4-nitrophenyl)-1H-1,2,3-triazol-4-yl]-2-methylphenyl]methyl]carbamate 2. The compound of claim 1, selected from the group consisting of:
8. 13. A fungicidal composition comprising: (a) a compound according to claim 1; and (b) at least one other fungicide.
9. 13. A germicidal composition comprising: (a) a compound according to claim 1; and (b) at least one additional component selected from the group consisting of a surfactant, a solid diluent, and a liquid diluent.
10. 13. A method for controlling plant diseases caused by fungal plant pathogens which comprises applying to a plant or part thereof, or to the seeds of a plant, a fungicidally effective amount of a compound of claim 1.
Citation Information
Patent Citations
Substituted benzene disinfectant / fungicide
JP2010523570A
Heterobicyclic substituted azolylbenzene fungicide / moldkiller
JP2013509408A
Substituted Tolyl fungicide and fungicide
JP2016505511A
Pyrrole, diazole, triazole or tetrazole derivatives suitable for controlling arthropods
JP2018526353A
Substituted tolyls as fungicides.
JP2022506507A
